INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1001, 0, 'Mirtazapine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1002, 0, 'Mirtazapine', 'Hyperlipidemias', 'Mirtazapine may significantly elevate serum triglyceride and total cholesterol levels.  Patients with preexisting hyperlipidemia may require closer monitoring during mirtazapine therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1003, 0, 'Mirtazapine', 'Hyponatremia', 'Treatment with mirtazapine can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1004, 0, 'Mirtazapine', 'Seizures', 'The use of tricyclic and tetracyclic antidepressants is associated with a risk of seizures.  Only one case of seizure was reported with mirtazapine, a newer tetracyclic antidepressant, during premarketing trials involving nearly 2800 patients.  However, the drug has not been evaluated in controlled studies of patients with a history of seizures.  Therapy with mirtazapine should be administered cautiously in such patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1005, 0, 'Mirtazapine', 'Glaucoma', 'Tetracyclic antidepressants as other type of antidepressants have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with anatomically narrow angle or history of glaucoma.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1006, 0, 'Minoxidil', 'Heart Failure', 'Minoxidil tablets must usually be administered with a diuretic to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required.  Body weight should be monitored closely.  If minoxidil is used without a diuretic, retention of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema.  Caution and close monitoring is advised in patients with preexisting congestive heart failure.  Pericardial effusion, occasionally with tamponade, has been also observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.  In some cases, the pericardial effusion was associated with a congestive heart failure, or marked fluid retention.  Rarely, refractory fluid retention may require discontinuation of minoxidil.  Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1007, 0, 'Minoxidil', 'Myocardial Ischemia', 'Minoxidil commonly produces reflex tachycardia.  Angina pectoris may develop or worsen as a result of increased oxygen demands associated with increased heart rate and cardiac output.  Therapy with minoxidil should be administered cautiously in patients with coronary insufficiency.  The concomitant administration of a beta-adrenergic blocker is often helpful to prevent tachycardia and increased myocardial workload.  Minoxidil has not been studied for use in patients who have had a recent myocardial infarction (within the preceding month).  It is possible that the reduction of arterial pressure and increase in heart rate produced by minoxidil may further limit blood flow to the myocardium.  Minoxidil must be administered under close supervision, also usually given with a diuretic, to prevent serious fluid accumulation.  Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1008, 0, 'Minoxidil', 'Pheochromocytoma', 'The use of minoxidil is contraindicated in patients with known or suspected pheochromocytoma.  Minoxidil may stimulate the secretion of catecholamines from the tumor through its antihypertensive action.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1009, 0, 'Minoxidil', 'Kidney Failure, Chronic', 'Patients with renal failure or on dialysis may require a lower dosage of minoxidil as 21% of a dose is excreted unchanged in the urine.  Close medical supervision is advised to prevent exacerbation of renal failure or precipitation of cardiac failure.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1010, 0, 'Mitomycin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1011, 0, 'Mitomycin', 'Hemorrhagic Disorders', 'The use of mitomycin is contraindicated in patients with thrombocytopenia, coagulation disorders, or an increase in bleeding tendency.  Mitomycin induces cumulative, delayed myelosuppression.  Neutropenia and thrombocytopenia can occur anytime within eight weeks after initiation of therapy.  Therapy with mitomycin should be withheld if platelet counts fall below 100,000/mm3 and subsequent dosages modified based on the nadir of the previous dose.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1012, 0, 'Mitomycin', 'Bone Marrow Failure Disorders', 'Mitomycin induces cumulative, delayed myelosuppression.  Neutropenia and thrombocytopenia can occur anytime within eight weeks after initiation of therapy.  Anemia occurs less frequently.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.  Therapy with mitomycin should be withheld if white blood cell counts fall below 4000/mm3 and/or platelet counts fall below 100,000/mm3 and subsequent dosages modified based on the nadir of the previous dose.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1013, 0, 'Mitomycin', 'Kidney Diseases', 'Elevations in BUN and/or serum creatinine have been reported during mitomycin therapy.  Therapy with mitomycin should not be administered to patients with serum creatinine > 1.7 mg/dl.  Hemolytic Uremic Syndrome (HUS) has been reported during mitomycin therapy. The incidence of HUS appears to be increased in patients receiving total doses of mitomycin > 60 mg.  Blood product transfusion may exacerbate the symptoms of HUS.  Clinical monitoring of renal function is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1014, 0, 'Miglitol', 'Diabetic Ketoacidosis', 'The use of alpha-glucosidase inhibitors is contraindicated for the treatment of patients with diabetic ketoacidosis.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1015, 0, 'Miglitol', 'Intestinal Diseases', 'The use of alpha-glucosidase inhibitors is contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, or any chronic intestinal disease associated with marked disorders of digestion or absorption.  Alpha-glucosidase inhibitors competitively inhibit enzymes involved in the digestion of carbohydrates.  Increased gas formation in the intestines due to fermentation of the undigested carbohydrates can worsen or aggravate intestinal problems.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1016, 0, 'Miglitol', 'Kidney Diseases', 'Miglitol is eliminated primarily by the kidney.  Plasma miglitol levels in patients with renal impairment have been shown to proportionally increase relative to the degree of renal dysfunction.  However, long-term clinical trials in diabetic patients with significant renal dysfunction (serum creatinine > 2.0 mg/dL) have not been conducted.  Therapy with miglitol should be administered cautiously in patients with renal insufficiency.  The manufacturer does not recommend its use in patients with significantly impaired renal function.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1017, 0, 'Migalastat', 'Kidney Diseases', 'Migalastat is substantially excreted by the kidneys.  No dosage adjustment is required in patients with mild to moderate renal impairment (eGFR at least 30 mL/min/1.73 m2 and above).  Migalastat is not recommended for use in patients with severe renal impairment or end-stage renal disease requiring dialysis.  Systemic exposure was significantly increased in subjects with severe renal impairment (eGFR less than 30 mL/min/1.73 m2).  Migalastat has not been studied in patients with Fabry disease who have an eGFR less than 30 mL/min/1.73 m2.  Care is recommended when using this agent in patients with renal impairment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1018, 0, 'Miltefosine', 'Sjogren-Larsson Syndrome', 'The use of miltefosine is contraindicated in patients with Sjogren-Larsson syndrome.  Miltefosine undergoes metabolic cleavage in hepatocytes to release choline.  The fatty alcohol-containing fragment of miltefosine is then oxidized to palmitic acid, which enters the metabolism of fatty acids.  However, this oxidation is blocked in patients with Sjogren-Larsson syndrome, who have a genetic defect in fatty aldehyde dehydrogenase activity.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1019, 0, 'Miltefosine', 'Liver Diseases', 'Elevations in liver transaminases (ALT, AST) and bilirubin were observed in clinical trials of miltefosine for the treatment of visceral leishmaniasis.  Patients with serum ALT or AST levels at least 3 times the upper limit of normal and bilirubin levels at least 2 times the upper limit of normal were excluded from clinical trials.  The pharmacokinetics of miltefosine have not been studied in patients with liver dysfunction; caution is recommended.  Liver transaminases (ALT, AST) and bilirubin should be monitored during therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1020, 0, 'Miltefosine', 'Kidney Diseases', 'Elevations in serum creatinine were observed in clinical trials of miltefosine for the treatment of cutaneous, mucosal, and visceral leishmaniasis.  Patients with serum creatinine or BUN levels at least 1.5 times the upper limit of normal were excluded from clinical trials.  The pharmacokinetics of miltefosine have not been studied in patients with renal dysfunction; caution is recommended.  Renal function should be monitored weekly during therapy and for 4 weeks after completion of therapy.  Abdominal pain, nausea, vomiting, and diarrhea are common side effects of miltefosine; patients should be advised to drink plenty of fluids to avoid dehydration (and, thus, the risk of kidney injury) and to seek medical attention if these gastrointestinal side effects are persistent or severe.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1021, 0, 'Miltefosine', 'Thrombocytopenia', 'Thrombocytopenia has been reported during treatment of visceral leishmaniasis, including with miltefosine.  Therapy with miltefosine should be administered cautiously in patients with preexisting thrombocytopenia.  Platelet counts should be monitored during therapy for visceral leishmaniasis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1022, 0, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1023, 0, 'Milnacipran', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1024, 0, 'Milnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1025, 0, 'Milnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1026, 0, 'Milnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1027, 0, 'Milnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1028, 0, 'Milnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1029, 0, 'Milnacipran', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1030, 0, 'Milnacipran', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1031, 0, 'Milnacipran', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1032, 0, 'Minocycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1033, 0, 'Minocycline', 'Liver Diseases', 'The use of tetracyclines has rarely been associated with hepatotoxicity.  Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs.  Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction.  Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling.  Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1034, 0, 'Minocycline', 'Kidney Diseases', 'Tetracyclines (except doxycycline) are eliminated by the kidney to various extent.  Patients with renal impairment may be at greater risk for tetracycline-associated hepatic and/or renal toxicity (increased BUN with consequent azotemia, hyperphosphatemia, and acidosis) due to decreased drug clearance.  Therapy with tetracyclines should be administered cautiously at reduced dosages in patients with renal impairment.  Clinical monitoring of renal and liver function is recommended, and serum tetracycline levels may be necessary during prolonged therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1035, 0, 'Minocycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1036, 0, 'Mitotane', 'Adrenal Insufficiency', 'Mitotane inhibits production of corticosteroids and alters extra-adrenal metabolism of endogenous and exogenous steroids.  All patients treated with mitotane should be instructed to immediately report signs and symptoms of infection or other illnesses.  Therapy with mitotane should be withheld immediately following shock or severe trauma or infection.  Exogenous steroids should be administered since the suppressed adrenal may not immediately begin to secrete steroids.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1037, 0, 'Mitotane', 'Depressive Disorder', 'Symptoms of depression consisting of lethargy and somnolence have been reported during mitotane therapy.  Therapy with mitotane should be administered cautiously to patients with or predisposed to depression.  Clinical monitoring of psychological behavior is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1038, 0, 'Mitotane', 'Liver Diseases', 'Mitotane is primarily metabolized by the liver.  Metabolism and therapeutic activity may be altered in patients with hepatic impairment.  Therapy with mitotane should be administered cautiously in patients with hepatic impairment.  Clinical monitoring of hepatic function is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1039, 0, 'Mitotane', 'Nervous System Diseases', 'Unspecified brain damage and impairment of function have been reported during prolonged mitotane therapy.  Therapy with mitotane should be administered cautiously to patients with neurologic impairment.  Clinical monitoring of behavior and neurological function is recommended when continuous mitotane therapy exceeds two years.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1040, 0, 'Mitotane', 'Perimenopause', 'Ovarian macrocysts, often bilateral and multiple, have been reported in premenopausal patients receiving mitotane which might lead to adnexal torsion and hemorrhagic cyst rupture.  It is recommended to use care when using this agent in premenopausal patients and to seek medical care if they experience gynecological symptoms such as vaginal bleeding and/or pelvic pain.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1041, 0, 'Mogamulizumab', 'Autoimmune Diseases', 'Fatal and life-threatening immune-mediated complications have been reported in recipients of mogamulizumab.  Grade 3 or higher immune-mediated or possibly immune-mediated reactions have included myositis, myocarditis, polymyositis, hepatitis, pneumonitis, and a variant of Guillain- BarrÃ© syndrome.  Interrupt or permanently discontinue therapy as appropriate for suspected immune-mediated adverse reactions.  Consider the benefit/risk of using mogamulizumab in patients with a history of autoimmune disease.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1042, 0, 'Mivacurium', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1043, 0, 'Mivacurium', 'Burns', 'Patients with burns may develop resistance to non-depolarizing neuromuscular blocking agents.  These patients may experience a shorter duration of action and/or require higher dosages of the drugs.  The extent of altered response depends on the duration since and the size of the burn.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1044, 0, 'Mivacurium', 'Hypersensitivity', 'Some neuromuscular blocking agents stimulate the release of histamine, which can cause wheezing, bronchospasm, increased bronchial secretions, hypotension, tachycardia, and circulatory collapse.  Hypotension may also occur due to ganglionic blockade or as a complication of positive pressure respiration.  Tubocurarine appears to be the most potent inducer of histamine, followed by metocurine (no longer commercially available in the U.S.) and succinylcholine.  Other agents with varying but lesser degrees of histamine-releasing properties include atracurium, mivacurium, and pancuronium (at excessive dosages).  Therapy with these neuromuscular blocking agents should be administered cautiously in patients with clinically significant cardiovascular disease and/or a history of asthma or severe allergic reactions.  Certain agents may prolong the QTc interval, especially during general anesthesia in pediatric patients.  The initial dosage and rate of administration may need to be reduced, and hemodynamic and respiratory status carefully monitored.  Neuromuscular blocking agents that appear to have little or no histamine-inducing effects include cisatracurium, doxacurium, pipecuronium, rocuronium, and vecuronium.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1045, 0, 'Mivacurium', 'Liver Diseases', 'Neuromuscular blocking agents undergo metabolism by the liver.  Elimination and effects may be prolonged in patients with liver disease.  Therapy with neuromuscular blocking agents should be administered cautiously in patients with liver disease.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1046, 0, 'Mivacurium', 'Myasthenia Gravis', 'The use of neuromuscular blocking agents may cause prolonged respiratory paralysis.  Therapy with neuromuscular blocking agents should be administered cautiously in patients with myasthenia gravis.  Use of a peripheral nerve stimulator may be helpful in evaluating the level of neuromuscular blockade.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1047, 0, 'Mivacurium', 'Paresis', 'Patients with hemiparesis or paraparesis may require higher dosages of non-depolarizing neuromuscular blocking agents in the affected limbs.  Neuromuscular monitoring should be performed on a non-paretic limb to avoid inaccurate dosing.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1048, 0, 'Mivacurium', 'Respiratory Insufficiency', 'Neuromuscular blocking agents can cause respiratory depression and paralysis.  Therapy with neuromuscular blocking agents should be administered cautiously in patients with pulmonary impairment.  Treatment of respiratory paralysis consists of positive-pressure artificial respiration with oxygen and maintenance of a patent airway until the recovery of normal respiration is assured.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1049, 0, 'Mivacurium', 'Obesity', 'A few of the neuromuscular blocking agents, including doxacurium, mivacurium and pipecuronium, may have prolonged and/or enhanced effects in obese patients (i.e. weight >= 30% over ideal body weight for height).  Dosing of these agents should be based on ideal body weight in obese patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1050, 0, 'Mivacurium', 'Kidney Diseases', 'Many of the non-depolarizing (competitive) neuromuscular blocking agents undergo significant elimination by the kidney.  Their effects may, therefore, be prolonged in patients with renal dysfunction.  Therapy with these neuromuscular blocking agents should be administered cautiously and initiated at reduced dosages in renally compromised patients, depending on the level of insufficiency.  If possible, alternative agents should be considered.  Atracurium, rocuronium and vecuronium do not depend on kidney function for clearance and are often the non-depolarizing muscle relaxants of choice in renal failure.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1051, 0, 'Ascorbic acid', 'Hemolysis', 'Acute hemolysis following administration of high doses of ascorbic acid in patients with glucose-6-phosphate deficiency (G6PD) has been reported.  Ascorbic acid should be administered cautiously and dosages modified in patients with G6PD.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1052, 0, 'Ascorbic acid', 'Kidney Calculi', 'Large doses of ascorbic acid have lead to hyperoxaluria in 5% of patients.  Ascorbic acid can acidify urine resulting in precipitation of urate, cystine, or oxalate stones.  Ascorbic acid should be administered cautiously and dosages modified in patients predisposed to renal stones.  Clinical monitoring of urinalysis for pH and crystal formation is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1053, 0, 'Ascorbic acid', 'Heart Failure', 'Ascorbic acid preparations contain sodium.  The sodium content should be considered when used in patients with sodium restricted diets and conditions require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1054, 0, 'Ascorbic acid', 'Diseases requiring dialysis', 'Ascorbic acid is removed by dialysis.', '1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1055, 0, 'Molindone', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1056, 0, 'Molindone', 'Central Nervous System Diseases', 'The use of most miscellaneous antipsychotics is contraindicated in patients with severe central nervous system depression or comatose states from any cause (e.g., lesion, disease, drug or alcohol induced).', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1057, 0, 'Molindone', 'Neuroleptic Malignant Syndrome', 'Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex, has been reported in association with the use of antipsychotic drugs.  The diagnostic evaluation is complicated and the management requires immediate discontinuation of the antipsychotic therapy and intensive symptomatic treatment and medical monitoring.  If a patient that has recovered from NMS requires antipsychotic drug treatment again, the reintroduction of therapy should be carefully considered as NMS recurrences have been reported.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1058, 0, 'Molindone', 'Epilepsy', 'Antipsychotics can lower the seizure threshold and trigger seizures in a dose-dependent manner.  Seizures have been reported in patients receiving antipsychotic therapy and may occur in epileptic patients even with maintenance of routine anticonvulsant treatment.  Therapy with antipsychotics should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.  High dosages should be avoided if possible.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1059, 0, 'Molindone', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1060, 0, 'Molindone', 'Cardiovascular Diseases', 'Neuroleptic agents may cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope and dizziness, particularly during initiation of therapy or rapid escalation of dosage.  Tolerance to the hypotensive effects often develops after a few doses to a few weeks.  Rarely, fatal cardiac arrest has occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include hypertension, edema, arrhythmias, thrombophlebitis, myocarditis, angina, myocardial infarction, congestive heart failure, and ECG abnormalities such as PR and QT interval prolongation, diffuse T-wave flattening, and ST segment depression.  Therapy with neuroleptic agents should be administered cautiously in patients with severe cardiovascular disease, pheochromocytoma, a predisposition to hypotension, or conditions that could be exacerbated by hypotension such as a history of myocardial infarction, angina, or ischemic stroke.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  If parenteral therapy is given, patients should be in a supine position during administration and for at least 30 to 60 minutes afterwards.  Patients who experience orthostatic hypotension should be cautioned not to rise too abruptly.  Occasionally, when severe, hypotension may require treatment with vasoconstrictive agents such as norepinephrine or phenylephrine.  Epinephrine should not be used, however, since neuroleptic agents can reverse its vasopressor effects and cause a further lowering of blood pressure.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1061, 0, 'Molindone', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1062, 0, 'Molindone', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1063, 0, 'Molindone', 'Hyperprolactinemia', 'Antipsychotic drugs can elevate serum prolactin concentrations, and this elevation persists during chronic administration.  This should be considered if therapy will be prescribed in patients with previously detected breast cancer as one-third of human breast cancers are prolactin-dependent in vitro.  Associated disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been reported.  Appropriate laboratory testing and follow-up is advised.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1064, 0, 'Molindone', 'Intestinal Obstruction', 'Some antipsychotics such as loxapine and molindone have antiemetic effects and may mask signs of overdosage of toxic drugs, and may obscure conditions such as intestinal obstruction and brain tumor.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1065, 0, 'Molindone', 'Neutropenia', 'The use of antipsychotics has been associated with events of leukopenia, neutropenia and agranulocytosis.  Possible risk factors include preexisting low white blood cell count, and history of drug induced leukopenia/neutropenia.  Patients with these risk factors should have complete blood count monitored frequently during the first few months of therapy.  Patients should also be monitored for any signs or symptoms of infection.  Treatment should be discontinued in any patient who develops a sore throat, fever, stomatitis, or other signs of infection along with a low WBC count or severe neutropenia (ANC < 1000/mm3).', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1066, 0, 'Molindone', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1067, 0, 'Molindone', 'Dehydration', 'Neuroleptic agents may cause hypotension (including orthostatic hypotension) and associated reflex tachycardia, syncope or dizziness, particularly during initiation of therapy or rapid escalation of dosage.  Tolerance to the hypotensive effects often develops after a few doses to a few months.  Rarely, fatal cardiac arrest has occurred secondary to severe hypotension.  Therapy with neuroleptic agents should be administered cautiously in patients with conditions that would predispose them to hypotension, such as hypovolemia or dehydration (e.g., due to severe diarrhea or vomiting).  In addition, neuroleptic agents can interfere with the body''s ability to regulate core body temperature, occasionally producing hyperthermia during strenuous exercise, exposure to hot weather, and concomitant treatment with anticholinergic medications.  Patients who are dehydrated may be particularly susceptible.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1068, 0, 'Molindone', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1069, 0, 'Molindone', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1070, 0, 'Molindone', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1071, 0, 'Mitoxantrone', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1072, 0, 'Mitoxantrone', 'Heart Diseases', 'Mitoxantrone can cause myocardial toxicity leading to congestive heart failure (CHF).  Patients with preexisting heart disease, prior irradiation, previous therapy with related compounds such as daunorubicin, idarubicin or doxorubicin, or of advanced age are at increased risk of cardiotoxicity at a lower cumulative dose.  The incidence of drug-induced congestive heart failure in adults is increased when the total cumulative dose of mitoxantrone exceeds 140 mg/m2.  Close clinical monitoring of cardiac function, such as determination of left ventricular ejection fraction, prior to each course of therapy is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1073, 0, 'Mitoxantrone', 'Liver Diseases', 'Hepatic impairment reduces mitoxantrone clearance.  Patients with severe hepatic dysfunction (bilirubin > 3.4 mg/dL) have an AUC more than three times greater than that of patients with normal hepatic function receiving the same dose.  Therapy with mitoxantrone should be administered cautiously to patients with significantly compromised hepatic function.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1074, 0, 'Mitoxantrone', 'Bone Marrow Failure Disorders', 'Mitoxantrone induces myelosuppression when administered at therapeutic doses indicated for treatment of leukemia.  Leukopenia is the most profound hematologic side-effect.  Thrombocytopenia is rare, but can be severe and erythrocytes do not appear to be significantly affected.  Therapy with mitoxantrone should be withheld in patients whose bone marrow function is severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  If the need outweighs the risk, extreme caution should be exercised in administering mitoxantrone.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitory of hematopoietic function is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1075, 0, 'Mitoxantrone', 'Hyperuricemia', 'Treatment with mitoxantrone may cause hyperuricemia as a result of rapid lysis of tumor cells.  Levels of serum uric acid should be monitored and appropriate therapy should be initiated before starting therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1076, 0, 'Modafinil', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1077, 0, 'Modafinil', 'Hypertension', 'CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.  Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.  All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1078, 0, 'Modafinil', 'Liver Diseases', 'In general, CNS stimulants are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly.  Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury.  Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1079, 0, 'Modafinil', 'Mental Disorders', 'The use of CNS stimulants can cause psychotic or maniac symptoms, suicidal ideation, aggression and can exacerbate symptoms of behavior disturbance and thought disorder.  Psychiatric symptoms have been reported in patients with and without history of psychiatric disorders, and all patients should be monitored closely, specially during treatment initiation and at times of dose changes.  Extreme caution should be exercised when CNS stimulants are given to patients with a history of psychosis, depression, mania, or bipolar disorder.  All patients receiving treatment should be screened for bipolar disease prior to initiation.  If any psychiatric symptoms emerge or are exacerbated, treatment suspension should be considered.  CNS stimulants are contraindicated in patients with marked agitation or anxiety.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1080, 0, 'Modafinil', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1081, 0, 'Modafinil', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1082, 0, 'Modafinil', 'Kidney Diseases', 'Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response.  The dosage should be adjusted accordingly.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1083, 0, 'Modafinil', 'Epilepsy', 'Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures.  These drugs may lower the convulsive threshold in patients with prior history of seizures or EEG abnormalities, and very rarely in patients with no previous history of seizures.  Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures.  If seizures appear, therapy should be discontinued.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1084, 0, 'Modafinil', 'Cardiovascular Diseases', 'In clinical trials, a few patients treated with modafinil developed chest pain, palpitations, dyspnea and transient ischemic T-wave changes in association with mitral valve prolapse or left ventricular hypertrophy.  The manufacturer recommends that modafinil not be used in patients with a history of left ventricular hypertrophy or ischemic ECG changes, chest pain, arrhythmia or other clinically significant manifestations of mitral valve prolapse in association with central nervous system (CNS) stimulant use.  In addition, caution is advised in patients with cardiovascular disease due to other causes, particularly hypertension and/or a recent history of myocardial infarction or unstable angina, since the use of modafinil has not been evaluated in such patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1085, 0, 'Moexipril', 'Angioedema', 'The use of these agents is contraindicated in patients with hereditary angioedema or a history of idiopathic angioedema.  Patients with a history of angioedema unrelated to ACE inhibitors may be at increased risk of angioedema while receiving an ACE inhibitor.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with ACE inhibitors should be discontinued permanently if angioedema develops in association with therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1086, 0, 'Moexipril', 'Bone Marrow Failure Disorders', 'ACE inhibitors may cause bone marrow suppression, rarely in uncomplicated individuals but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma.  Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, eosinophilia and thrombocytopenia have been reported, mostly with captopril.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting blood dyscrasias or complications that may increase the risk of bone marrow depression during ACE inhibitor therapy.  Monitoring of blood counts, particularly white blood cells, should be considered.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1087, 0, 'Moexipril', 'Heart Failure', 'ACE inhibitors can cause marked renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic and sometimes excessive hypotension can occur in susceptible individuals, particularly during the initiation of treatment, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with ACE inhibitors may be associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia and death.  Therapy with ACE inhibitors should be initiated under very close medical supervision in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  Patients should be monitored closely for several hours after an initial dose until blood pressure has stabilized, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.  If feasible, the risk of severe hypotension may be minimized by reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days prior to starting ACE inhibitor therapy.  In patients who experience a worsening of renal function, discontinuation of ACE inhibitor therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with ACE inhibitors.  After blood pressure stabilizes, therapy can usually be reinstated with caution, although a lower dosage of the ACE inhibitor and/or dosage reduction or discontinuation of concomitantly administered diuretics may be necessary.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1088, 0, 'Moexipril', 'Diseases requiring hemodialysis', 'Anaphylactoid reactions have been reported in patients undergoing hemodialysis with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor.  The frequency and mechanism of this interaction have not been established, and it is not known whether the interaction occurs with other membrane types.  Therapy with ACE inhibitors should be administered cautiously in patients requiring hemodialysis.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1089, 0, 'Moexipril', 'Hyperkalemia', 'In patients with hyperkalemia, especially those associated with impaired renal function or congestive heart failure, ACE inhibitors may further raise serum potassium levels.  Therapy with ACE inhibitors should be administered cautiously in patients with or predisposed to hyperkalemia, and serum potassium levels should be carefully monitored.  Risk factors for the development of hyperkalemia during ACE inhibitor therapy include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1090, 0, 'Moexipril', 'Hypotension', 'ACE inhibitors can cause symptomatic hypotension, most often during the initiation of therapy and in patients who are volume- and/or sodium-depleted or treated for congestive heart failure (CHF).  Therapy with ACE inhibitors should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if it was recently instituted; those on dietary salt restriction; those with severe or prolonged diarrhea or vomiting; and renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with ACE inhibitors, and the patient should be hemodynamically stable.  If concomitant diuretics and/or dietary sodium restriction are employed, reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days in advance can help minimize the risk of severe hypotension in patients who are able to tolerate such adjustments.  ACE inhibitors should also be used cautiously in patients in whom excessive hypotension may have serious consequences, such as patients with coronary or cerebrovascular insufficiency.  Patients at risk for excessive hypotension should initiate ACE inhibitor therapy under very close medical supervision, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1091, 0, 'Moexipril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1092, 0, 'Moexipril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1093, 0, 'Monopotassium phosphate', 'Hypocalcemia', 'The use of phosphates is in general contraindicated in conditions where high potassium, high phosphate, or low calcium may be encountered such as hypoparathyroidism, osteomalacia, acute pancreatitis, or chronic renal disease.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1094, 0, 'Monopotassium phosphate', 'Renal Insufficiency', 'Potassium phosphate injections contains aluminum that may be toxic.  Aluminum may reach toxic levels with prolonged parenteral administration in patients with renal impairment.  Preterm infants are particularly at risk for aluminum toxicity because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which also contain aluminum.  Patients with renal impairment, including preterm infants, who receive greater than 4 to 5 mcg/kg/day of parenteral aluminum can accumulate aluminum to levels associated with central nervous system and bone toxicity.  Potassium phosphate injection for parenteral nutrition is not recommended in adults weighing less than 45 kg or pediatric patients less than 12 years of age or weighing less than 40 kg due to the risks of aluminum toxicity.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1095, 0, 'Monopotassium phosphate', 'Heart Diseases', 'Potassium phosphate injection may increase the risk of hyperkalemia.  Patients with cardiac disease may be more susceptible to the effects of hyperkalemia.  Caution is advised when using potassium phosphates in patients with heart disease.  Continuous electrocardiographic (ECG) monitoring is recommended for higher infusion rates of potassium.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1096, 0, 'Monopotassium phosphate', 'Hypomagnesemia 1, Intestinal', 'Intravenous infusion of phosphate has been reported to cause a decrease in serum magnesium (and calcium) concentrations when administered to patients with hypercalcemia and diabetic ketoacidosis.  Monitor serum magnesium concentrations during treatment.  Caution is advised in patients with magnesium imbalances.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1097, 0, 'Montelukast', 'Mental Disorders', 'The use of montelukast is associated with neuropsychiatric events.  Patients and prescribers should be alert for neuropsychiatric events.  Care should be taken before using this agent in patients with any history of mental illness.  If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1098, 0, 'Montelukast', 'Liver Failure', 'Reports of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury have been reported in patients treated with montelukast sodium that had underlying potential for liver disease, such as alcohol use or other forms of hepatitis.  Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast.  No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency.  The pharmacokinetics of montelukast sodium in patients with more severe hepatic impairment or with hepatitis have not been evaluated.  Use caution when prescribing montelukast to these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1099, 0, 'Montelukast', 'Phenylketonurias', 'Singulair (brand of montelukast) chewable tablets contain 0.842 mg of phenylalanine per each 5 mg tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1100, 0, 'Montelukast', 'Respiration Disorders', 'Patients with asthma on therapy with montelukast may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy.  Prescribers should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients.  Care should be taken before using this agent in patients with history of pulmonary disorders.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1101, 0, 'Morphine', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1102, 0, 'Morphine', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1103, 0, 'Morphine', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1104, 0, 'Morphine', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1105, 0, 'Morphine', 'Alcoholic Intoxication', 'The use of opiate agonists is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of opiate agonists may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with opiate agonists should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1106, 0, 'Morphine', 'Substance-Related Disorders', 'Opiate agonists have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use.  Abrupt cessation, reduction in dosage, or administration of an opiate antagonist such as naloxone may precipitate withdrawal symptoms.  In patients who have developed tolerance to an opiate agonist, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1107, 0, 'Morphine', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1108, 0, 'Morphine', 'Hypotension', 'Opiate agonists can induce vasodilation and significant hypotension, particularly when given in high dosages and/or by rapid intravenous administration.  Opiate analgesics cause vasodilatation that may exacerbate hypotension and hypoperfusion and, therefore, are contraindicated in circulatory shock.  At therapeutic analgesic dosages, ambulatory patients are more likely to experience dizziness and hypotension than patients who are confined to bed.  However, orthostatic hypotension may occur in supine patients upon rising.  Therapy with opiate agonists should be administered cautiously and initiated at reduced dosages in patients with hypovolemia, or a predisposition to hypotension.  When given by intramuscular or subcutaneous administration, clinicians should also be aware that impaired perfusion in these patients may prevent complete absorption of the drug.  With repeated injections, an excessive amount may be absorbed suddenly if normal circulation is reestablished.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1109, 0, 'Morphine', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate agonists, particularly by the intravenous route, can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Opiate agonists should not be used in patients with suspected or known head injury or increased intracranial pressure.  Also, clinicians treating such patients should be aware that opiate agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1110, 0, 'Morphine', 'Respiratory Insufficiency', 'Opiate agonists may produce significant central nervous system and respiratory depression of varying duration, particularly when given in high dosages and/or by rapid intravenous administration.  Apnea may result from decreased respiratory drive as well as increased airway resistance, and rigidity of respiratory muscles may occur during rapid IV administration or when these agents are used in the induction of anesthesia.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS depression; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral or neuraxial routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression, which may be prolonged depending on the opioid agent, cumulative dose, and route of administration.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1111, 0, 'Morphine', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1112, 0, 'Morphine', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1113, 0, 'Morphine', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1114, 0, 'Morphine', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1115, 0, 'Morphine', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1116, 0, 'Morphine', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1117, 0, 'Morphine', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1118, 0, 'Morphine', 'Intestinal Pseudo-Obstruction', 'Morphine liposomal, as with all opiates, diminishes propulsive peristaltic waves in the gastrointestinal tract and may prolong obstruction; therefore, its use is contraindicated in any patient who has or is suspected of having paralytic ileus.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1119, 0, 'Moricizine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1120, 0, 'Moricizine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1121, 0, 'Moricizine', 'Water-Electrolyte Imbalance', 'Electrolyte imbalance can alter the therapeutic effectiveness of antiarrhythmic agents.  Hypokalemia and hypomagnesemia can reduce the effectiveness of antiarrhythmic agents.  In some cases, these disorders can exaggerate the degree of QTc prolongation and increase the potential for torsade de pointes.  Hyperkalemia can potentiate the toxic effects of antiarrhythmic agents.  Electrolyte imbalance should be corrected prior to initiating antiarrhythmic therapy.  Clinical monitoring of cardiac function and electrolyte concentrations is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1122, 0, 'Asenapine', 'Liver Failure', 'Asenapine is contraindicated in patients with severe hepatic impairment (Child-Pugh C).  Asenapine is a high clearance drug and its exposure has shown to be 7-fold higher in subjects with severe hepatic impairment than the exposure observed in subjects with normal hepatic function.  No dosage adjustment for asenapine is required in patients with mild to moderate hepatic impairment (Child-Pugh A and B) because the drug exposure is similar to that in subjects with normal hepatic function.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1123, 0, 'Asenapine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1124, 0, 'Asenapine', 'Long QT Syndrome', 'Some atypical antipsychotic agents can prolong the QTc interval of the electrocardiogram in a dose-dependent manner.  Electrolyte disturbances such as hypokalemia and hypomagnesemia may augment the prolongation effect of these agents on the QT interval and should be corrected prior to institution of therapy.  In addition, patients who experience frequent, severe, or prolonged diarrhea may be subject to electrolyte losses and should be followed closely and managed accordingly during therapy with these agents.  Atypical antipsychotic agents should be avoided in patients with a history of cardiac arrhythmias or other conditions that may increase the risk of torsade de pointes and/or sudden death, including bradycardia; hypokalemia or hypomagnesemia; and congenital long QT syndrome.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1125, 0, 'Asenapine', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1126, 0, 'Asenapine', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1127, 0, 'Asenapine', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1128, 0, 'Asenapine', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1129, 0, 'Asenapine', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1130, 0, 'Asenapine', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1131, 0, 'Asenapine', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1132, 0, 'Asenapine', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1133, 0, 'Asenapine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1134, 0, 'Asenapine', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1135, 0, 'Asenapine', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1136, 0, 'Muromonab', 'Cardiomyopathies', 'The use of muromonab-CD3 is contraindicated in patients with uncompensated heart failure.  Cardiovascular collapse, cardiac arrest, severe hypotension, shock, left ventricular dysfunction, and arrhythmias have occurred in patients administered muromonab-CD3.  Patients with cardiovascular impairments are at increased risk for more serious cardiorespiratory complications (respiratory arrest, failure, distress, and/or cardiovascular collapse, cardiac arrest, angina, or myocardial infarction) from muromonab-CD3-associated Cytokine Release Syndrome.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1137, 0, 'Muromonab', 'Psychotic Disorders', 'The use of muromonab-CD3 is contraindicated in patients with or predisposed to seizures.  Seizures,  cerebral edema, confusion, auditory/visual hallucinations, mental status changes, psychosis, mania, lethargy, stupor, or coma have occurred in patients administered muromonab-CD3.  Patient with CNS disorders, cerebrovascular disease,  neurological disturbances are at increased risk for neuro/psychiatric events.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1138, 0, 'Muromonab', 'Edema', 'The use of muromonab-CD3 is contraindicated in patients with fluid overload as evidences by chest X-ray or a 3% or more weight gain in the week prior to muromonab-CD3 therapy.  Patients with fluid overload are at increased risk for more serious cardiopulmonary complications (respiratory arrest, failure, distress, and/or cardiovascular collapse, cardiac arrest, angina, or myocardial infarction) from muromonab-CD3-associated Cytokine Release Syndrome.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1139, 0, 'Muromonab', 'Fever', 'Muromonab-CD3 should not be administered in the presence of a body temperature of 100 degrees F  (38.7 degrees C) or greater.  Spiking fever (to 107 degrees F) associated with the Cytokine Release Syndrome have occurred.  Antipyretics may be administered to reduce body temperature in this setting.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1140, 0, 'Mycophenolate mofetil', 'Neutropenia', 'Severe neutropenia has occurred in up to 2% of patients administered mycophenolate.  Therapy with mycophenolate should be administered cautiously in patients with or predisposed to neutropenia.  Mycophenolate should be discontinued or the dose reduced in patients who develop neutropenia (absolute neutrophil count <1300/mm3).   Clinical monitoring of hematopoietic function is recommended.  Complete blood counts should be performed weekly during the first month,  two times a month during the second and third months, and monthly for the remainder of the first year of treatment.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1141, 0, 'Mycophenolate mofetil', 'Gastrointestinal Hemorrhage', 'Gastrointestinal, rectal, and duodenal hemorrhage, hemorrhagic pancreatitis and rarely, large-intestine perforation have occurred in patients receiving mycophenolate.  These events occurred primarily at dosages of mycophenolate >2 grams per day.  Therapy with mycophenolate should be administered cautiously in patients with active gastrointestinal disease.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1142, 0, 'Mycophenolate mofetil', 'Liver Diseases', 'Mycophenolate mofetil (inactive) undergoes complete presystemic metabolism to active MPA , further metabolism to inactive forms, some of which undergo enterohepatic circulation producing a second peak of MPA.   Alcoholic cirrhosis (parenchymal cell damage) does not appear to affect the metabolism of MPA to inactive forms.  Hepatic disease/dysfunction due to other etiologies may induce different effects.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1143, 0, 'Mycophenolate mofetil', 'Kidney Diseases', 'Mycophenolate undergoes complete presystemic metabolism to its active form, MPA .  Less than 1% of  MPA is excreted in the urine.  In a single-dose study, the area under the curve (AUC) for MPA in patients with severe chronic renal impairment (creatinine clearance <25 mL/min) was approximately 75% greater than those of healthy volunteers (creatinine clearance >80 mL/min).  The AUC for the inactive  metabolite was 3 to 6 times higher.  Multiple dose studies have not been performed.  No data are available for cardiac transplant patients with severe renal impairment and when benefit outweighs risk, therapy with mycophenolate should be administered with extreme caution.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1144, 0, 'Mycophenolate mofetil', 'Lesch-Nyhan Syndrome', 'Mycophenolate mofetil is an inosine monophosphate dehydrogenase (IMPDH) inhibitor; therefore it should be avoided in patients with hereditary deficiencies of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndromes because it may cause an exacerbation of disease symptoms characterized by the overproduction and accumulation of uric acid leading to symptoms associated with gout such as acute arthritis, tophi, nephrolithiasis or urolithiasis and renal disease including renal failure.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1145, 0, 'Moxifloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1146, 0, 'Moxifloxacin', 'Liver Diseases', 'Moxifloxacin is primarily metabolized by the liver via glucuronide and sulfate conjugation and may accumulate in patients with impaired hepatic function.  Therapy with moxifloxacin should be administered cautiously in patients with liver disease.  Dosage adjustments are not necessary in patients with mild hepatic insufficiency (Child Pugh Class A).  Due to a lack of clinical data, use is not recommended in patients with moderate or severe hepatic insufficiency.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1147, 0, 'Moxifloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1148, 0, 'Moxifloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1149, 0, 'Moxifloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1150, 0, 'Moxifloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1151, 0, 'Moxifloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1152, 0, 'Moxifloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1153, 0, 'Moxifloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1154, 0, 'Nalmefene', 'Liver Failure', 'Opiate antagonists are metabolized by the liver (naltrexone to an active metabolite) and eliminated by the kidney.  Hepatic and renal impairment may reduce the metabolism and clearance of opiate antagonists.  Dosage adjustment for single dose administration is not necessary, however, repeated doses in patients with hepatic and/or renal dysfunction may require adjustment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1155, 0, 'Nalidixic acid', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1156, 0, 'Nalidixic acid', 'Liver Diseases', 'Nalidixic acid is primarily metabolized by the liver and may accumulate in patients with impaired hepatic function.  Therapy with nalidixic acid should be administered cautiously in patients with liver disease.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1157, 0, 'Nalidixic acid', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1158, 0, 'Nalidixic acid', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1159, 0, 'Nalidixic acid', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1160, 0, 'Nalidixic acid', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1161, 0, 'Nalidixic acid', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1162, 0, 'Nalidixic acid', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1163, 0, 'Mycophenolic acid', 'Infections', 'Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents.  Patients receiving immunosuppressants are at increased risk of developing bacterial, viral, fungal, and protozoal infections, and new or reactivated viral infections including opportunistic infections.  Caution should be exercised when considering their use in patients with severe or chronic infections.  It is recommended to interrupt therapy in patients who develop a new infection while undergoing treatment and to monitor these patients closely for any sign or symptom indicative of infection.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1164, 0, 'Mycophenolic acid', 'Leukoencephalopathy, Progressive Multifocal', 'Immunosuppressive agents may increase the risk of progressive multifocal leukoencephalopathy (PML).  Certain agents are contraindicated in patients who have or have had PML.  Patients receiving chronic immunosuppressant or immunomodulatory therapy or who have systemic medical conditions resulting in significantly compromised immune system function should not be treated with these agents.  Healthcare professionals should monitor patients for any new sign or symptom suggestive of PML.  Withhold therapy dosing immediately and perform an appropriate diagnostic evaluation at the first sign or symptom suggestive of PML.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1165, 0, 'Mycophenolic acid', 'Lesch-Nyhan Syndrome', 'The use of mycophenolic acid should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndromes because it may cause an exacerbation of disease symptoms.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1166, 0, 'Mycophenolic acid', 'Gastrointestinal Diseases', 'The use of mycophenolic acid may cause gastrointestinal bleeding (requiring hospitalization), intestinal perforations, gastric ulcers, and duodenal ulcers.  Mycophenolic acid should be administered with caution in patients with active serious digestive system disease.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1167, 0, 'Mycophenolic acid', 'Skin Neoplasms', 'The use of mycophenolic acid increases the risk of developing lymphomas and other malignancies, particularly of the skin.  Patients with increased risk for skin cancer, exposure to sunlight and UV light should be limited by wearing protective clothing and using a sunscreen with a high protection factor.  Care should be exercised when using mycophenolic acid in patients with these conditions.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1168, 0, 'Nafcillin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1169, 0, 'Nafcillin', 'Hematologic Diseases', 'The use of penicillinase-resistant penicillins has been associated with adverse hematologic effects, including neutropenia, leukopenia, granulocytopenia and thrombocytopenia, particularly when given in high parenteral dosages.  Agranulocytosis and prolonged bleeding time have been reported rarely.  Therapy with penicillinase-resistant penicillins should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow depression, and hematopoietic function should be monitored.  Blood counts with differential should be performed prior to initiation of therapy and 1 to 3 times weekly during therapy.  Hematologic abnormalities are generally reversible and resolve within several days to two weeks following discontinuation of therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1170, 0, 'Nafcillin', 'Liver Diseases', 'Nafcillin is primarily metabolized by the liver but also partially excreted unchanged by the kidney.  The serum concentration of nafcillin may be increased and the half-life prolonged in patients with significantly impaired renal and/or hepatic function.  In general, dosage adjustments are not necessary in either renal or hepatic impairment alone, but may be appropriate in patients with both renal and hepatic failure.  Renal and liver function tests should be performed periodically during prolonged therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1171, 0, 'Nafcillin', 'Water-Electrolyte Imbalance', 'Each gram of parenteral nafcillin sodium contains approximately 67 mg (2.9 mEq) of sodium and is buffered with 40 mg of sodium citrate.  Each 250 mg capsule of nafcillin sodium contains approximately 17 mg (0.7 mEq) of sodium buffered with calcium carbonate.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  In addition, hypokalemia has been reported rarely during therapy with the penicillinase-resistant penicillins, which may be particularly important to bear in mind when treating patients with low potassium reserves or fluid and electrolyte imbalance.  Clinical monitoring of electrolytes is recommended if these agents are used for prolonged periods.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1172, 0, 'Nabilone', 'Heart Diseases', 'The use of some antiemetics such as dronabinol and nabilone has been associated with occasional hypotension, possible hypertension, syncope or tachycardia.  Therapy with these drugs should be administered cautiously in patients with cardiac disease.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1173, 0, 'Nabilone', 'Psychotic Disorders', 'Some antiemetics such as dronabinol and nabilone may precipitate or exacerbate psychotic symptoms or anxiety, depression, hallucinations or psychosis.  Therapy with these drugs should be administered cautiously in patients with a history of psychiatric disorders, emotional instability, or depression, and particularly if they are elderly.  Careful psychiatric monitoring is advised.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1174, 0, 'Nabilone', 'Substance-Related Disorders', 'Some antiemetics as dronabinol and nabilone have a significant potential for abuse.  Therapy with these drugs should be administered cautiously in patients with a history of substance abuse.  It may be prudent to refrain from dispensing large quantities of dronabinol to these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1175, 0, 'Nabilone', 'Long QT Syndrome', 'The effects of QT prolongation potential by nabilone have not been studies.  Caution and monitoring is advised if used in patients with long QT syndrome.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1176, 0, 'Nadolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1177, 0, 'Nadolol', 'Shock, Cardiogenic', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with hypotension or cardiogenic shock.  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to further depress cardiac output and blood pressure, which can be detrimental in these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1178, 0, 'Nadolol', 'Heart Failure', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with overt congestive heart failure (CHF).  Sympathetic stimulation may be important in maintaining the hemodynamic function in these patients, thus beta-blockade can worsen the heart failure.  However, therapy with beta-blockers may be beneficial and can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Carvedilol, specifically, is indicated for use with these agents in the treatment of mild to severe heart failure of ischemic or cardiomyopathic origin.  There is also increasing evidence that the addition of a beta-blocker to standard therapy can improve morbidity and mortality in patients with advanced heart failure, although it is uncertain whether effectiveness varies significantly with the different agents.  Data from one meta-analysis study suggest a greater reduction of mortality risk for nonselective beta-blockers than for beta-1 selective agents.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1179, 0, 'Nadolol', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since cardioselectivity is not absolute, larger doses of beta-1 selective agents may demonstrate these effects as well.  Therapy with beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1180, 0, 'Nadolol', 'Diseases requiring hemodialysis', 'Therapy with beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in patients requiring hemodialysis.  When given after dialysis, hemodynamic stability should be established prior to drug administration to avoid marked falls in blood pressure.  The hemodynamic status should be closely monitored before and after the dose.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1181, 0, 'Nadolol', 'Hypersensitivity', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1182, 0, 'Nadolol', 'Myocardial Ischemia', 'Heightened sensitivity to catecholamines may occur after prolonged use of beta-adrenergic receptor blocking agents (aka beta-blockers).  Exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following abrupt withdrawal of therapy.  Cessation of beta-blocker therapy, whenever necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks in patients with coronary insufficiency.  Patients should be advised not to discontinue treatment without first consulting with the physician.  In patients who experience an exacerbation of angina following discontinuation of beta-blocker therapy, the medication should generally be reinstituted, at least temporarily, along with other clinically appropriate measures.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1183, 0, 'Nadolol', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1184, 0, 'Nadolol', 'Kidney Diseases', 'Nadolol is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from nadolol due to decreased drug clearance.  Therapy with nadolol should be administered cautiously in patients with renal impairment.  Dosage adjustments (i.e. prolongation of dosing interval) are recommended for patients with moderate to severe renal dysfunction (CrCl <= 50 mL/min).', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1185, 0, 'Nadolol', 'Asthma', 'Some beta-adrenergic receptor blocking agents (i.e., non-cardioselective beta-blockers) are contraindicated in patients with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease.  In general, beta-adrenergic receptor blocking agents should not be used in patients with bronchospastic diseases.  Beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  If beta-blocker therapy is necessary in these patients, an agent with beta-1 selectivity (e.g., atenolol, metoprolol, betaxolol) is considered safer, but should be used with caution nonetheless.  Cardioselectivity is not absolute and can be lost with larger doses.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1186, 0, 'Nadolol', 'Cerebrovascular Disorders', 'Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1187, 0, 'Nadolol', 'Glaucoma', 'Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1188, 0, 'Nadolol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1189, 0, 'Nadolol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1190, 0, 'Nadolol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1191, 0, 'Nadolol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1192, 0, 'Nadolol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1193, 0, 'Nadolol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1194, 0, 'Nadolol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1195, 0, 'Naratriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1196, 0, 'Naratriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1197, 0, 'Naratriptan', 'Liver Diseases', 'The manufacturer considers the use of naratriptan to be contraindicated in patients with severe hepatic impairment (Child-Pugh grade C).  Naratriptan is partially metabolized by the liver.  In patients with moderate hepatic impairment (Child-Pugh grade A or B), the clearance of naratriptan has been shown to decrease by 30% compared to healthy controls, resulting in an approximately 40% increase in the mean half-life.  A lower initial dosage should be considered in patients with mild or moderate hepatic impairment, and the maximum dosage should not exceed 2.5 mg per 24-hour period.  There are no data concerning the use of naratriptan in patients with severe hepatic impairment, thus it is not recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1198, 0, 'Naratriptan', 'Kidney Diseases', 'The manufacturer considers the use of naratriptan to be contraindicated in patients with severe renal impairment (CrCl < 15 mL/min).  Naratriptan is primarily eliminated by the kidney, approximately 50% as parent drug and 30% as metabolites.  In patients with moderate renal impairment (CrCl = 18 to 39 mL/min), the clearance of naratriptan has been shown to decrease by 50% compared to healthy controls, resulting in an approximately 83% increase in the mean half-life.  A lower initial dosage should be considered in patients with mild or moderate renal impairment, and the maximum dosage should not exceed 2.5 mg per 24-hour period.  There are no data concerning the use of naratriptan in patients with severe renal impairment, thus it is not recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1199, 0, 'Nateglinide', 'Diabetes Mellitus, Type 1', 'The use of meglitinides is contraindicated in patients with type I diabetes or for the treatment of diabetic ketoacidosis, with or without coma.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1200, 0, 'Nateglinide', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1201, 0, 'Nateglinide', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1202, 0, 'Nateglinide', 'Liver Diseases', 'Nateglinide is primarily metabolized in the liver to both pharmacologically active and inactive substances.  Patients with impaired liver function may be exposed to higher concentrations of nateglinide and its associated metabolites.  Higher serum drug levels, in addition to diminished gluconeogenic capacity secondary to hepatic insufficiency, may increase the potential for severe hypoglycemic episodes.  Therapy with nateglinide should be administered cautiously in patients with liver disease.  Dosage adjustments may be necessary in moderate to severe hepatic impairment, although clinical data are lacking.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1203, 0, 'Naltrexone', 'Liver Diseases', 'The use of naltrexone is contraindicated in patients with active hepatitis or hepatic failure.  Naltrexone has caused direct hepatocellular injury when administered at doses less than or equal to 5 times the recommended once daily 50 mg dose.  Therapy with naltrexone should be administered cautiously in patients with active hepatic disease.  Clinical monitoring of transaminase levels prior to and during naltrexone therapy  is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1204, 0, 'Naltrexone', 'Liver Failure', 'Opiate antagonists are metabolized by the liver (naltrexone to an active metabolite) and eliminated by the kidney.  Hepatic and renal impairment may reduce the metabolism and clearance of opiate antagonists.  Dosage adjustment for single dose administration is not necessary, however, repeated doses in patients with hepatic and/or renal dysfunction may require adjustment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1205, 0, 'Naloxone', 'Cardiovascular disease', 'Therapy with naloxone in patients with preexisting cardiovascular disorders should be closely monitored for hypotension, hypertension, ventricular tachycardia or fibrillation, and pulmonary edema in an appropriate healthcare setting.  Clinical monitoring of cardiovascular status is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1206, 0, 'Naloxone', 'Liver Diseases', 'The safety and effectiveness of naloxone injection in patients with liver disease have not been established.  Caution should be exercised when naloxone is administered to patients with liver disease.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1207, 0, 'Naloxone', 'Kidney Failure, Chronic', 'The safety and effectiveness of naloxone injection in patients with renal insufficiency/failure have not been established.  Caution should be exercised when naloxone is administered to these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1208, 0, 'Naloxone', 'Shock, Septic', 'Naloxone has been shown in some cases of septic shock to produce a rise in blood pressure that may last up to several hours; however, this pressor response has not been demonstrated to improve patient survival.  In some studies, treatment with naloxone in the setting of septic shock has been associated with adverse effects, including agitation, nausea and vomiting, pulmonary edema, hypotension, cardiac arrhythmias, and seizures.  The decision to use naloxone in septic shock should be exercised with caution, particularly in patients who may have underlying pain or have previously received opioid therapy and may have developed opioid tolerance.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1209, 0, 'Naldemedine', 'Hepatic Insufficiency', 'The use of naldemedine should be avoided in patients with severe hepatic impairment.  No dose adjustment is required in patients with mild or moderate hepatic impairment.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1210, 0, 'Naldemedine', 'Intestinal Obstruction', 'Peripheral opioid receptor antagonists are contraindicated in patients with known or suspected gastrointestinal obstruction, and in patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation.  Cases of gastrointestinal perforation have been reported in patients with opioid-induced constipation and advanced illness with conditions that may be associated with localized or diffuse reduction of structure integrity in the wall of the GI tract such as peptic ulcer, diverticular disease, Crohn''s disease, infiltrative GI tract malignancies or peritoneal metastases.  It is recommended to monitor for the development of severe, persistent, or worsening abdominal pain and to discontinue treatment in patients who develop symptoms.  The overall risk- benefit profile should be carefully evaluated before using these agents in patients with these conditions.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1211, 0, 'Naldemedine', 'Diseases requiring hemodialysis', 'Naldemedine is not removed from the blood by hemodialysis.  Plasma concentrations of naldemedine in subjects with ESRD requiring hemodialysis were similar when the drug was administered either pre- or post-hemodialysis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1212, 0, 'Naphazoline (nasal)', 'Prostatic Hyperplasia', 'Topically applied sympathomimetic agents are systemically absorbed, with the potential for producing clinically significant systemic effects, particularly during prolonged or indiscriminate use.  In patients with prostate enlargement, urinary difficulty may develop or worsen due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors.  Therapy with topical sympathomimetic agents should be administered cautiously in patients with hypertrophy or neoplasm of the prostate.  It is important that the recommended dosages of the individual products not be exceeded.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1213, 0, 'Naphazoline (nasal)', 'Cardiovascular Diseases', 'Topically applied sympathomimetic agents are systemically absorbed, with the potential for producing clinically significant systemic effects, particularly during prolonged or indiscriminate use.  In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta-1 adrenergic receptors.  Cardiac output, oxygen consumption, and the work of the heart may be increased.  In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors.  Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, and coronary occlusion have been reported rarely during the use of ophthalmic and nasal sympathomimetic agents, but may be more likely if the corneal epithelium is damaged or if an excessive amount of drug is swallowed during nasal administration.  Therapy with topical sympathomimetic agents should be administered cautiously in patients with corneal abrasion, sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders, especially coronary insufficiency, cardiac arrhythmia, or hypertension.  The potent ophthalmic formulations (e.g., phenylephrine 2.5% or 10%) that are used for diagnostic and pre-surgical purposes should not be used in such patients.  For other preparations, it is important that the recommended dosages of the individual products not be exceeded.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1214, 0, 'Naphazoline (nasal)', 'Diabetes Mellitus', 'Topically applied sympathomimetic agents are systemically absorbed, particularly during prolonged or indiscriminate use.  Slight increases in blood glucose concentrations may occur with the use of these drugs.  Therapy with topical sympathomimetic agents should be administered cautiously in patients with diabetes mellitus.  Closer monitoring of blood glucose concentrations may be appropriate.  It is important that the recommended dosages of the individual products not be exceeded.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1215, 0, 'Nalbuphine', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1216, 0, 'Nalbuphine', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1217, 0, 'Nalbuphine', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1218, 0, 'Nalbuphine', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1219, 0, 'Nalbuphine', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1220, 0, 'Nalbuphine', 'Myocardial Infarction', 'Opiate partial agonists may increase systemic and pulmonary arterial pressure and systemic vascular resistance, particularly when given by intravenous administration.  Data are available for pentazocine and butorphanol.  Therapy with opiate partial agonists should be administered cautiously and only if the benefit justifies the risk in patients with acute myocardial infarction (especially if accompanied by hypertension or left ventricular failure) or coronary insufficiency.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1221, 0, 'Nalbuphine', 'Substance-Related Disorders', 'Opiate partial agonists have the potential to cause dependence and abuse, particularly in patients with a history of drug abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use, and abrupt cessation or a significant reduction in dosage may precipitate withdrawal symptoms.  Because of their opiate antagonistic effect, withdrawal symptoms may also occur if opiate partial agonists are administered to patients with an opiate dependence or in whom substantial amounts of narcotics have recently been administered.  Therapy with opiate partial agonists is not recommended in patients who are physically dependent on narcotics.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate partial agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1222, 0, 'Nalbuphine', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate partial agonists can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Unless mechanical ventilation is provided, extreme caution is advised when opiate partial agonists are given to patients head injury, intracranial lesions, or a preexisting elevated CSF pressure.  Also, clinicians treating such patients should be aware that opiate partial agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1223, 0, 'Nalbuphine', 'Respiratory Insufficiency', 'Opiate partial agonists may produce respiratory depression by decreasing respiratory drive and increasing airway resistance.  A "ceiling effect" has been noted for these agents, and increasing doses do not produce proportional or further respiratory depression.  However, the duration of effect is prolonged.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate partial agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS or respiratory depression; acute alcohol intoxication; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate partial agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression.  However, in the case of buprenorphine, naloxone may not be effective due to buprenorphine''s slow rate of dissociation from mu receptors.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1224, 0, 'Nalbuphine', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1225, 0, 'Nalbuphine', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1226, 0, 'Nalbuphine', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1227, 0, 'Nalbuphine', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1228, 0, 'Nalbuphine', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1229, 0, 'Nalbuphine', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1230, 0, 'Natalizumab', 'Infections', 'Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents.  Patients receiving immunosuppressants are at increased risk of developing bacterial, viral, fungal, and protozoal infections, and new or reactivated viral infections including opportunistic infections.  Caution should be exercised when considering their use in patients with severe or chronic infections.  It is recommended to interrupt therapy in patients who develop a new infection while undergoing treatment and to monitor these patients closely for any sign or symptom indicative of infection.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1231, 0, 'Natalizumab', 'Leukoencephalopathy, Progressive Multifocal', 'Immunosuppressive agents may increase the risk of progressive multifocal leukoencephalopathy (PML).  Certain agents are contraindicated in patients who have or have had PML.  Patients receiving chronic immunosuppressant or immunomodulatory therapy or who have systemic medical conditions resulting in significantly compromised immune system function should not be treated with these agents.  Healthcare professionals should monitor patients for any new sign or symptom suggestive of PML.  Withhold therapy dosing immediately and perform an appropriate diagnostic evaluation at the first sign or symptom suggestive of PML.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1232, 0, 'Natalizumab', 'Liver Diseases', 'Postmarketing reports have associated the use of natalizumab with severe hepatic toxicity, including acute liver failure requiring transplant.  Natalizumab should be discontinued in patients with jaundice or other evidence of significant liver injury and appropriate therapy should be instituted according to clinical guidelines.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1233, 0, 'Natalizumab', 'Meningitis', 'Natalizumab increases the risk of developing encephalitis and meningitis caused by herpes simplex and varicella zoster viruses.  It is recommended to monitor patients receiving natalizumab for signs and symptoms of meningitis and encephalitis.  If herpes encephalitis or meningitis occurs, treatment should be discontinued, and appropriate treatment for herpes encephalitis/meningitis should be administered.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1234, 0, 'Nabumetone', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1235, 0, 'Nabumetone', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1236, 0, 'Nabumetone', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1237, 0, 'Nabumetone', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1238, 0, 'Nabumetone', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1239, 0, 'Nabumetone', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1240, 0, 'Nabumetone', 'Liver Diseases', 'The biotransformation of nabumetone to its active metabolite (6-methoxy-2-naphthylacetic acid, or 6MNA) and the further metabolism of 6MNA to inactive substances are dependent upon hepatic function and could be reduced in patients with severe hepatic impairment.  The protein binding of 6MNA may also be altered in liver disease.  Clinical data concerning the potential consequences of these effects are limited.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1241, 0, 'Nabumetone', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1242, 0, 'Nabumetone', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1243, 0, 'Nabumetone', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1244, 0, 'Nabumetone', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1245, 0, 'Nabumetone', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1246, 0, 'Naloxegol', 'Hepatic Insufficiency', 'The effect of severe hepatic impairment (Child-Pugh Class C) on the pharmacokinetics of naloxegol has not been evaluated, so the use of this drug should be avoided in patients with this condition.  No dose adjustment is required for patients with mild or moderate hepatic impairment.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1247, 0, 'Naloxegol', 'Intestinal Obstruction', 'Peripheral opioid receptor antagonists are contraindicated in patients with known or suspected gastrointestinal obstruction, and in patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation.  Cases of gastrointestinal perforation have been reported in patients with opioid-induced constipation and advanced illness with conditions that may be associated with localized or diffuse reduction of structure integrity in the wall of the GI tract such as peptic ulcer, diverticular disease, Crohn''s disease, infiltrative GI tract malignancies or peritoneal metastases.  It is recommended to monitor for the development of severe, persistent, or worsening abdominal pain and to discontinue treatment in patients who develop symptoms.  The overall risk- benefit profile should be carefully evaluated before using these agents in patients with these conditions.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1248, 0, 'Naloxegol', 'Kidney Diseases', 'Patients with moderate, severe and end-stage renal disease have shown to exhibit markedly higher systemic exposure to peripheral opioid receptor antagonists such as methylnaltrexone and naloxegol, compared to subjects with normal renal function.  A dose reduction is recommended for these patients.  No dosage adjustment is needed in patients with mild renal impairment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1249, 0, 'Naproxen', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1250, 0, 'Naproxen', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1251, 0, 'Naproxen', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1252, 0, 'Naproxen', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1253, 0, 'Naproxen', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1254, 0, 'Naproxen', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1255, 0, 'Naproxen', 'Heart Failure', 'Anaprox and Anaprox DS (brands of naproxen sodium) contain 25 mg and 50 mg of sodium per tablet (approximately 1 mEq/250 mg naproxen), respectively, and Naprosyn suspension contains 39 mg per teaspoonful (approximately 1.5 mEq/125 mg naproxen).  The sodium content should be considered when these products are used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1256, 0, 'Naproxen', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1257, 0, 'Naproxen', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1258, 0, 'Naproxen', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1259, 0, 'Naproxen', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1260, 0, 'Naproxen', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1261, 0, 'Naxitamab', 'Hypertension', 'The use of naxitamab can cause hypertension.  Do not initiate naxitamab in patients with uncontrolled hypertension.  It is recommended to monitor blood pressure during infusion, and at least daily on Days 1 to 8 of each cycle and evaluate for complications of hypertension including reversible posterior leukoencephalopathy syndrome.  Interrupt infusion and resume at a reduced rate, or permanently discontinue naxitamab based on the severity of symptoms.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1262, 0, 'Necitumumab', 'Water-Electrolyte Imbalance', 'The use of certain EGFR inhibitors has been associated with progressive decreases in serum magnesium levels leading to severe cases of hypomagnesemia and accompanying electrolyte abnormalities, including hypocalcemia, and hypokalemia.  The onset of hypomagnesemia and accompanying electrolyte abnormalities occurred days to months after initiation of these agents.  Periodically monitor patients for hypomagnesemia, hypocalcemia, and hypokalemia, during and for at least 8 weeks following the completion of therapy.  Caution is recommended when using these agents in patients predisposed to electrolyte imbalances and those with a history of coronary artery disease, congestive heart failure, or arrhythmias.  Replete magnesium and other electrolytes as appropriate.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1263, 0, 'Necitumumab', 'Stevens-Johnson Syndrome', 'Cutaneous reactions, in some cases severe, have been reported with the use of EGFR inhibitors.  Monitor patients who develop dermatologic or soft tissue toxicities while receiving these agents for the development of inflammatory or infectious sequelae.  It is recommended to withhold treatment, and appropriate measures should be instituted as appropriate or discontinue the use of these agents for dermatologic or soft tissue toxicity associated with severe or life-threatening inflammatory or infectious complications.  Advise patients to wear sunscreen and hats and limit sun exposure while receiving therapy with these agents as exposure to sunlight can exacerbate dermatologic toxicities.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1264, 0, 'Necitumumab', 'Eye Diseases', 'Some epidermal growth factor receptor (EGFR) inhibitors should be administered cautiously in patients with ocular disorders such as primary keratitis, ulcerative keratitis, or conjunctivitis.  It is recommended to interrupt or discontinue treatment with these agents if patients present with acute or worsening ocular disorders.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1265, 0, 'Necitumumab', 'Thromboembolism', 'Venous and arterial thromboembolic events (VTE and ATE), some fatal, were observed with necitumumab in combination with gemcitabine and cisplatin.  Caution is recommended when using necitumumab in patients with a reported history of VTE or ATE.  Necitumumab should be discontinued in patients with serious or life threatening VTE or ATE.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1266, 0, 'Necitumumab', 'Hepatic Insufficiency', 'No formal studies have been conducted to evaluate the effect of renal and hepatic impairment on the exposure to necitumumab.  Renal function and mild or moderate hepatic impairment has no influence on the exposure to necitumumab based on the population pharmacokinetic analysis.  No data is available for patients with severe hepatic impairment.  Cation and monitoring is recommended for these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1267, 0, 'Nebivolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1268, 0, 'Nebivolol', 'Shock, Cardiogenic', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with hypotension or cardiogenic shock.  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to further depress cardiac output and blood pressure, which can be detrimental in these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1269, 0, 'Nebivolol', 'Heart Failure', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with overt congestive heart failure (CHF).  Sympathetic stimulation may be important in maintaining the hemodynamic function in these patients, thus beta-blockade can worsen the heart failure.  However, therapy with beta-blockers may be beneficial and can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Carvedilol, specifically, is indicated for use with these agents in the treatment of mild to severe heart failure of ischemic or cardiomyopathic origin.  There is also increasing evidence that the addition of a beta-blocker to standard therapy can improve morbidity and mortality in patients with advanced heart failure, although it is uncertain whether effectiveness varies significantly with the different agents.  Data from one meta-analysis study suggest a greater reduction of mortality risk for nonselective beta-blockers than for beta-1 selective agents.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1270, 0, 'Nebivolol', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since cardioselectivity is not absolute, larger doses of beta-1 selective agents may demonstrate these effects as well.  Therapy with beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1271, 0, 'Nebivolol', 'Hypersensitivity', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1272, 0, 'Nebivolol', 'Myocardial Ischemia', 'Heightened sensitivity to catecholamines may occur after prolonged use of beta-adrenergic receptor blocking agents (aka beta-blockers).  Exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following abrupt withdrawal of therapy.  Cessation of beta-blocker therapy, whenever necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks in patients with coronary insufficiency.  Patients should be advised not to discontinue treatment without first consulting with the physician.  In patients who experience an exacerbation of angina following discontinuation of beta-blocker therapy, the medication should generally be reinstituted, at least temporarily, along with other clinically appropriate measures.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1273, 0, 'Nebivolol', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1274, 0, 'Nebivolol', 'Hepatic Insufficiency', 'Metabolism of nebivolol is decreased in patients with moderate hepatic impairment.  d-Nebivolol peak plasma concentration increased 3-fold, exposure (AUC) increased 10-fold, and the apparent clearance decreased by 86% in patients with moderate hepatic impairment (Child-Pugh Class B).  Patients with liver disease may be at greater risk for adverse effects from nebivolol due to decreased drug clearance.  Therapy with nebivolol should be administered cautiously in patients with liver disease.  Dosage adjustments may be necessary.  No formal studies have been performed in patients with severe hepatic impairment and nebivolol should be contraindicated for these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1275, 0, 'Nebivolol', 'Cerebrovascular Disorders', 'Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1276, 0, 'Nebivolol', 'Glaucoma', 'Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1277, 0, 'Nebivolol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1278, 0, 'Nebivolol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1279, 0, 'Nebivolol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1280, 0, 'Nebivolol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1281, 0, 'Nebivolol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1282, 0, 'Nebivolol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1283, 0, 'Nebivolol', 'Asthma', 'Patients with bronchospastic disease, should, in general, not receive beta blockers, including cardioselective beta-blockers.  Because of the relative beta-1 selectivity, cardioselective beta-blockers may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment.  Because beta-1 selectivity is not absolute, the lowest possible dose of these agents should be used.  Consider administering in smaller doses to avoid the higher plasma levels associated with the longer dosing intervals.  If dosage must be increased, dividing the dose should be considered to achieve lower peak blood levels.  It is recommended to have bronchodilators, including beta-2 agonists, readily available or administered concomitantly if necessary.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1284, 0, 'Nebivolol', 'Kidney Diseases', 'Renal clearance of nebivolol is decreased in patients with severe renal impairment.  The apparent clearance of nebivolol was unchanged following a single 5 mg dose of nebivolol in patients with mild renal impairment (CrCl 50 to 80 mL/min, n =7), and it was reduced negligibly in patients with moderate (CrCl 30 to 50 mL/min, n =9), but clearance was reduced by 53% in patients with severe renal impairment (CrCl<30 mL/min, n =5).  Patients with severe renal impairment may be at greater risk for adverse effects from nebivolol due to decreased drug clearance.  Therapy with nebivolol should be administered cautiously in patients with severe renal impairment.  Dosage adjustments may be necessary.  No studies have been conducted in patients on dialysis', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1285, 0, 'Nelarabine', 'Neurotoxicity Syndromes', 'Severe neurologic adverse reactions have been reported with the use of nelarabine.  Neurotoxicity is the dose-limiting toxicity of nelarabine.  Patients treated previously or concurrently with intrathecal chemotherapy or previously with craniospinal irradiation may be at increased risk for neurologic adverse events.  Close monitoring for neurologic adverse reactions is strongly recommended, when using nelarabine and therapy should be discontinued for neurologic adverse reactions of NCI Common Toxicity Criteria Grade 2 or greater.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1286, 0, 'Nelarabine', 'Bone Marrow Failure Disorders', 'Leukopenia, thrombocytopenia, anemia, and neutropenia, including febrile neutropenia, have been associated with nelarabine therapy.  Care should be instituted when using this agent in patients with hematologic complications.  Complete blood counts including platelets should be monitored regularly.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1287, 0, 'Nelarabine', 'Liver Diseases', 'The influence of hepatic impairment on the pharmacokinetics of nelarabine has not been evaluated.  Because the risk of adverse reactions to this drug may be greater in patients with severe hepatic impairment (total bilirubin greater than 3 times upper limit of normal), it is recommended to closely monitor patients with severe liver dysfunction when treated with nelarabine.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1288, 0, 'Nelarabine', 'Kidney Diseases', 'Nelarabine is a prodrug of the cytotoxic deoxyguanosine analogue, 9-beta-D-arabinofuranosylguanine (ara-G).  The pharmacokinetics of nelarabine and ara-G have not been specifically studied in renally impaired or hemodialyzed patients.  Nelarabine is excreted by the kidney to a small extent (5% to 10% of the administered dose).  Ara-G is excreted by the kidney to a greater extent (20% to 30% of the administered nelarabine dose) and Ara-G clearance decreased as renal function decreased.  Because the risk of adverse reactions to this drug may be greater in patients with moderate (CrCl 30 to 50 mL/min) or severe (CrCl less than 30 mL/min) renal impairment, it is recommended that these patients be closely monitored for toxicities when treated.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1289, 0, 'Nelarabine', 'Tumor Lysis Syndrome', 'Patients receiving nelarabine should receive intravenous hydration according to standard medical practice for the management of hyperuricemia in patients at risk for tumor lysis syndrome.  Consideration should be given to the use of allopurinol in patients at risk of hyperuricemia.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1290, 0, 'Nelfinavir', 'Hemophilia A', 'There have been postmarketing reports of increased bleeding, including spontaneous skin hematomas and hemarthrosis, in types A and B hemophiliac patients treated with protease inhibitors.  However, a causal relationship has not been established.  In some patients, additional Factor VIII was given.  In more than half of the reported cases, protease inhibitor therapy was continued or reintroduced following an interruption.  Hemophiliacs and patients with other coagulation defects should be monitored closely for bleeding during protease inhibitor therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1291, 0, 'Nelfinavir', 'Liver Diseases', 'Nelfinavir is primarily metabolized by the liver.  Patients with liver disease may be at greater risk for adverse effects from nelfinavir due to decreased drug clearance.  Therapy with nelfinavir should be administered cautiously in patients with liver disease.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1292, 0, 'Nelfinavir', 'Phenylketonurias', 'Viracept (brand of nelfinavir) oral powder contains 11.2 mg of phenylalanine per each gram of powder.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1293, 0, 'Nelfinavir', 'Hyperglycemia', 'New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, glucose intolerance, hyperglycemia, and some cases of diabetic ketoacidosis have been reported during postmarketing surveillance in HIV-infected patients treated with protease inhibitors (PIs).  In some cases, glucose abnormalities/hyperglycemia persisted despite discontinuation of PI therapy.  Frequently, insulin resistance may accompany fat redistribution and serum lipid elevations in what is collectively termed the HIV-associated lipodystrophy syndrome.  Although a causal relationship has not been established, these metabolic disturbances have most often occurred in HIV-infected patients during treatment with potent antiretroviral regimens containing PIs.  Monitoring patients for hyperglycemia, new onset diabetes mellitus, or exacerbation of diabetes mellitus should be considered during PI therapy.  Dosage adjustments in insulin or oral hypoglycemic medications may be necessary in patients with diabetes.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1294, 0, 'Nelfinavir', 'Hyperlipidemias', 'Hyperlipidemia has been observed in 10% of patients receiving ritonavir during clinical trials.  Increases of 30% to 40% from baseline have been reported for total cholesterol and 200% to 300% or more for triglycerides.  These effects have also been reported during postmarketing experience with other protease inhibitors (PIs) but may be the most dramatic with ritonavir.  The clinical significance of these elevations is unclear.  Severe hyperlipidemia is known to sometimes cause pancreatitis.  In addition, some patients have reportedly developed symptomatic atherosclerosis and coronary artery disease after initiating PI treatment.  Patients with preexisting hyperlipidemia may require closer monitoring during PI therapy, and adjustments made accordingly in their lipid-lowering regimen.  PI therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1295, 0, 'Nefazodone', 'Hypotension', 'Nefazodone has alpha-1 adrenergic blocking activity and may cause significant decreases in blood pressure, including orthostatic hypotension, in approximately 5% of patients.  Therapy with nefazodone should be administered cautiously in patients with preexisting hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with nefazodone.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1296, 0, 'Nefazodone', 'Liver Diseases', 'In general, treatment with nefazodone should not be initiated in patients with active liver disease or elevated baseline serum transaminase levels.  Cases of hepatic failure resulting in death or liver transplant, at an estimated rate of 1 per 250,000 to 300,000 patient-years of nefazodone treatment in the U.S. (approximately 3 to 4 times the background rate), have been reported during postmarketing use.  The time to liver injury for the reported cases typically ranged from 2 weeks to 6 months of use.  Dark urine and nonspecific prodromal symptoms (e.g., nausea, anorexia, malaise, gastrointestinal complaints) were reported in some, but not all, cases prior to the onset of jaundice.  There is no evidence that preexisting liver disease increases the likelihood of developing liver failure.  However, baseline abnormalities can delay the recognition or confound the diagnosis of a drug-induced hepatotoxic effect, thus use of nefazodone is discouraged in this population.  In patients who do receive nefazodone therapy, routine liver function testing should be considered to permit early detection of hepatic injury.  Nefazodone therapy should be promptly discontinued if clinical signs or symptoms suggestive of liver injury occur, or if serum transaminase levels exceed 3 times the upper limit of normal.  Therapy should be permanently discontinued in patients with presumed or confirmed drug-induced hepatotoxicity.  In addition, the use of nefazodone is contraindicated in patients who were withdrawn from nefazodone because of evidence of liver injury.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1297, 0, 'Nefazodone', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1298, 0, 'Nefazodone', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1299, 0, 'Nefazodone', 'Seizures', 'The use of most antidepressants is associated with a risk of seizures.  There have been only rare reports of convulsions, including grand mal seizures, following the administration of nefazodone or trazodone.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with a history of seizures.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1300, 0, 'Nefazodone', 'Depressive Disorder', 'Adults, young adults and children patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  Phenylpiperazine antidepressants are not approved for use in pediatric patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1301, 0, 'Neostigmine', 'Bradycardia', 'Due to their pharmacological action, cholinesterase inhibitors can have a vagotonic effect on the sinoatrial and atrioventricular nodes producing bradycardia or heart block.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with preexisting bradycardia or underlying cardiac conduction abnormalities.  Syncopal episodes have been reported in patients with and without cardiac abnormalities.  Atropine may be used to reverse bradycardia produced by cholinesterase inhibitors.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1302, 0, 'Neostigmine', 'Bronchial Spasm', 'Cholinesterase inhibitors inhibit the hydrolysis of acetylcholine.  The enhanced effect of acetylcholine produces constriction of the bronchi, increased bronchial secretions, and bronchospasm.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with respiratory dysfunction, history of asthma or obstructive pulmonary disease.  Monitoring respiratory function during dosage initiation and adjustment is recommended.  Use of atropine along with discontinuation of the cholinesterase inhibitor may be required for serious respiratory distress.  Neostigmine may produce more severe muscarinic side effects than does pyridostigmine and ambenonium.  However, the duration of action is longest for ambenonium and shortest for edrophonium.  Echothiophate iodide ophthalmic may be systemically absorbed and cautious use is recommended in these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1303, 0, 'Neostigmine', 'Coronary Artery Disease', 'The use of cholinesterase inhibitors  has been associated with a constriction of coronary arteries.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with coronary artery disease.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1304, 0, 'Neostigmine', 'Parkinsonian Disorders', 'Cholinesterase inhibitors should be used with caution in patients with parkinsonism.  Some of these drugs might be contraindicated in these patients (refer to specific prescribing information).  Symptoms of Parkinson''s disease may be exacerbated with the increase in cholinergic activity.  Caregivers and patients should be advised.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1305, 0, 'Neostigmine', 'Peptic Ulcer', 'The use of cholinesterase inhibitors is associated with an increase in gastric acid secretion and gastric contractions.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with peptic ulcer disease.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1306, 0, 'Neostigmine', 'Seizures', 'Cholinesterase inhibitors have been associated with convulsions and tremor.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1307, 0, 'Neostigmine', 'Hyperthyroidism', 'Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors.  Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism.  Monitoring of thyroid levels is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1308, 0, 'Neomycin (topical)', 'Tympanic Membrane Perforation', 'Like other aminoglycosides, neomycin is potentially ototoxic, both to vestibular and to auditory functions.  Therapy with neomycin otic preparations should be administered cautiously in patients with chronic otitis media or a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1309, 0, 'Neomycin (topical)', 'Burns', 'Topical aminoglycosides should not be used on serious burns.  When applied locally, aminoglycosides are generally not absorbed to a significant extent through intact skin but readily absorbed through denuded, burned, or granulating skin.  Systemic adverse effects of aminoglycosides include nephrotoxicity and ototoxicity to vestibular and auditory functions.  In general, topical aminoglycosides should not be used on large areas of the body or for more than 7 days without medical supervision.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1310, 0, 'Neomycin', 'Dehydration', 'Adequate hydration is crucial to minimize the risk of oto- and nephrotoxicity associated with the use of aminoglycosides.  Dehydration should preferably be corrected prior to initiation of therapy.  In patients who may be at risk for dehydration, such as those with severe and/or prolonged diarrhea or vomiting, fluid status should be monitored closely.  If signs of renal irritation develop during therapy, hydration should be increased as indicated, accompanied by a reduction in dosage if necessary.  Therapy should be withdrawn if urinary output decreases progressively or azotemia increases.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1311, 0, 'Neomycin', 'Neuromuscular Diseases', 'Aminoglycosides can cause dose-related neuromuscular blockade and muscle weakness, particularly in patients with neuromuscular disease or hypocalcemia and in patients receiving general anesthetics, neuromuscular blocking agents, or massive transfusions of citrate-anticoagulated blood.  Although aminoglycoside- induced neuromuscular blockade is generally self-limiting, it may rarely result in respiratory paralysis.  Neomycin is thought to be the most potent neuromuscular blocking agent in the class.  However, the risk is greatest with intraperitoneal or intrapleural instillation of large doses or rapid intravenous administration of parenteral aminoglycosides.  Therapy with aminoglycosides should be administered cautiously in patients with neuromuscular disorders (e.g., myasthenia gravis, parkinsonian syndrome, botulism) or hypocalcemia.  If signs of respiratory paralysis occur during aminoglycoside therapy, the drug should be discontinued and mechanical respiratory assistance provided if necessary.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1312, 0, 'Neomycin', 'Ototoxicity', 'Aminoglycosides can cause eighth cranial nerve damage, resulting in vestibular and/or auditory toxicities.  Symptoms include dizziness, nystagmus, vertigo, ataxia, tinnitus, and varying degrees of hearing impairment.  Permanent hearing loss may occur, including, rarely, total or partial irreversible bilateral deafness after the drug has been discontinued.  Therapy with aminoglycosides, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting vestibular and/or auditory impairment, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, patients should be adequately hydrated, the usual aminoglycoside dosage should not be exceeded, use with other ototoxic agents should be avoided, and peak and trough serum aminoglycoside concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Serial audiograms should be obtained in patients old enough to be tested, since loss of high- frequency perception usually precedes clinical hearing loss.  The dosage should be reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1313, 0, 'Neomycin', 'Kidney Diseases', 'Aminoglycosides are potentially oto- and nephrotoxic.  Eighth cranial nerve damage may manifest as vestibular and/or auditory toxicities, including dizziness, nystagmus, vertigo, ataxia, tinnitus, and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by tubular necrosis; increases in BUN, nonprotein nitrogen, and serum creatinine concentration; decreases in urine specific gravity and creatinine clearance; proteinuria; and cells or casts in the urine.  Rarely, renal electrolyte wasting may occur, resulting in hypocalcemia, hypomagnesemia, and hypokalemia that may be associated with paresthesia, tetany, confusion, and positive Chvostek and Trousseau signs.  Although aminoglycoside- induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred rarely.  Therapy with aminoglycosides should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, patients should be adequately hydrated, the usual aminoglycoside dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and peak and trough serum aminoglycoside concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1314, 0, 'Neomycin', 'Intestinal Obstruction', 'The use of oral aminoglycosides is contraindicated in patients with intestinal obstruction.  Orally administered aminoglycosides are poorly absorbed from the gastrointestinal tract and primarily eliminated unchanged in the feces.  Drug retention and enhanced systemic absorption may occur in the presence of intestinal obstruction, increasing the risk of oto- and nephrotoxicity associated with these drugs.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1315, 0, 'Neomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1316, 0, 'Neomycin', 'Gastroenteritis', 'The use of neomycin oral solution is contraindicated in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of neomycin.  Like other aminoglycosides, neomycin is potentially oto- and nephrotoxic, and systemic exposure should be avoided if possible.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1317, 0, 'Neratinib', 'Liver Diseases', 'Neratinib is mainly metabolized in the liver and its use has been associated with hepatotoxicity characterized by increased liver enzymes.  Patients with severe, preexisting hepatic impairment (Child Pugh Class C) experienced a reduction in neratinib clearance and an increase in C max and AUC.  It is recommended to reduce the starting dose of neratinib to 80 mg in patients with severe hepatic impairment (Child Pugh C).  Measure total bilirubin, AST, ALT, and alkaline phosphatase prior to starting treatment and monthly for the first 3 months of treatment, then every 3 months while on treatment and as clinically indicated.  No dose modifications are recommended for patients with mild to moderate hepatic impairment (Child Pugh A or B).', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1318, 0, 'Nepafenac (ophthalmic)', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1319, 0, 'Nesiritide', 'Hypotension', 'Nesiritide may cause hypotension and should be administered in settings where blood pressure can be monitored closely and hypotension can be aggressively treated.  The use of nesiritide is not recommended in patients for whom vasodilation agents are not appropriate, such as patients with significant valvular stenosis, restrictive or obstructive cardiomyopathy, constrictive pericarditis, pericardial tamponade, or other conditions in which cardiac output is dependent upon venous return.  The use of nesiritide is contraindicated in patients with persistent systolic blood pressure below 100 mm Hg prior to therapy because of an increased risk of symptomatic hypotension, and in patients in cardiogenic shock.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1320, 0, 'Nesiritide', 'Kidney Diseases', 'Nesiritide may decrease renal function as judged by increases in serum creatinine which should be monitored both during and after treatment has been completed, and until values have been stabilized.  Use care when administering this agent to patients with renal impairment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1321, 0, 'Nevirapine', 'Liver Diseases', 'The use of nevirapine has been associated with severe, life-threatening, and fatal hepatotoxicity, particularly in the first 18 weeks of therapy.  Fulminant and cholestatic hepatitis, hepatic necrosis, and hepatic failure have been reported.  Nevirapine-induced hepatitis and hepatic failure may be associated with signs of hypersensitivity, which can include severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial edema, eosinophilia, granulocytopenia, lymphadenopathy, or renal dysfunction.  In controlled clinical trials, symptomatic hepatic events regardless of severity occurred on average in 4% (range 0% to 11%) of patients who received nevirapine and 1.2% of patients in control groups.  The risk was greatest in the first 6 weeks of therapy and continued to be greater in the nevirapine groups compared to controls through 18 weeks of treatment.  In general, the patients at greatest risk of hepatic events are women with high CD4 counts.  During the first 6 weeks of treatment, women have a 3-fold higher risk than men for symptomatic, often rash-associated, hepatic events (5.8% vs. 2.2%).  In a retrospective review, women with CD4 counts greater than 250 cells/mm3 had a 12-fold higher risk of symptomatic hepatic events compared to women with lower CD4 counts (11% vs. 0.9%).  A 5-fold increased risk was observed in men with CD4 counts greater than 400 cells/mm3 compared to men with lower CD4 counts (6.3% vs. 1.2%).  Additionally, coinfection with hepatitis B or C and/or increased liver function tests at the start of therapy are associated with a greater risk of later symptomatic events (6 weeks or more after starting nevirapine) and asymptomatic increases in AST or ALT.  Therapy with nevirapine should be administered cautiously in patients with preexisting liver disease or liver function test abnormalities.  Due to the risk of drug accumulation, nevirapine should not be administered to patients with severe hepatic impairment.  All patients treated with nevirapine should undergo intensive clinical and laboratory monitoring (i.e., once a month or more) during the first 18 weeks of therapy, and regular monitoring thereafter.  Liver function tests should be performed at baseline, prior to dose escalation, and at two weeks post-dose escalation.  Patients should be instructed to discontinue nevirapine and seek medical attention promptly if signs and symptoms of hepatic injury or hypersensitivity develop such as fever, pruritus, rash, facial edema, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice.  Nevirapine should be permanently discontinued if clinical hepatitis or transaminase elevations combined with rash or other systemic symptoms occur, and should not be restarted after recovery.  In some cases, hepatic injury progresses despite discontinuation of treatment.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1322, 0, 'Nevirapine', 'Exanthema', 'Nevirapine can cause severe, life-threatening skin reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions characterized by rash, constitutional findings, and organ dysfunction including hepatic failure.  Fatalities in association with these reactions have been reported.  The first 6 weeks of therapy is the period of greatest risk, and intense monitoring is recommended during the first 18 weeks.  In controlled clinical trials, Grade 3 and 4 rashes were reported during the first 6 weeks in 1.5 % of nevirapine-treated patients compared to 0.1% of placebo subjects.  Patients who develop signs or symptoms of severe skin reactions or hypersensitivity reactions possibly related to nevirapine at any time during therapy must discontinue the drug and seek medical attention immediately.  Because nevirapine-induced hepatitis and hepatic failure may be associated with hypersensitivity reactions, liver function tests should be performed in these patients as well as all patients who develop a rash within the first 18 weeks of treatment.  Nevirapine should be permanently discontinued if clinical hepatitis or transaminase elevations combined with rash or other systemic symptoms occur, and should not be restarted after recovery.  Nevirapine therapy should also not be restarted following severe skin or hypersensitivity reactions or a rash that is accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial edema, eosinophilia, granulocytopenia, lymphadenopathy, or renal dysfunction.  During the initial 2-week lead-in period of 200 mg/day (4 mg/kg/day in pediatric patients), the dosage of nevirapine should not be increased if any rash occurs.  Dose escalation should only be attempted after the rash resolves.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1323, 0, 'Nevirapine', 'Diseases requiring hemodialysis', 'Nevirapine is partially removed by hemodialysis.  In a pharmacokinetic study of nevirapine in patients with renal impairment, six subjects requiring hemodialysis exhibited a 44% reduction in nevirapine systemic exposure (AUC) over a one-week period.  There was also evidence of accumulation of nevirapine hydroxy-metabolites in plasma in these patients; however, the clinical significance is unknown.  A supplemental dose following each dialysis session is indicated for patients undergoing chronic hemodialysis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1324, 0, 'Nevirapine', 'Kidney Diseases', 'Nevirapine metabolites are primarily eliminated by the kidney.  The clinical significance of possible reduced metabolite clearance in renal impairment is uncertain.  Therapy with nevirapine should be administered cautiously in patients with renal impairment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1325, 0, 'Niacin', 'Coronary Artery Disease', 'The Coronary Drug Project (1975) reported a significant increase in cardiac arrhythmias associated with the use of niacin at lipid-lowering dosages.  Treatment using pharmacologic dosages of niacin and niacinamide (nicotinamide) should be administered cautiously in patients with coronary heart disease or arrhythmias.  Particular caution is advised in the presence of unstable angina or in the acute phase of myocardial infarction, especially if the patient is also receiving vasoactive drugs such as nitrates, calcium channel blockers, or adrenergic blocking agents.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1326, 0, 'Niacin', 'Liver Diseases', 'The use of nicotinic acid and its derivatives at dosages substantially exceeding those for physiologic requirements is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  Hepatotoxicity, including biochemical abnormalities of liver function, cholestatic jaundice, increased prothrombin time, and fulminant hepatic necrosis and failure, has been reported during therapy with niacin and niacinamide (nicotinamide), particularly in patients who have substituted sustained-release nicotinic acid products for immediate-release preparations at equivalent dosages.  Treatment using pharmacologic dosages (e.g., lipid-lowering dosages) of these agents should be administered cautiously in patients with gallbladder disease or a history of jaundice, liver disease and/or heavy alcohol use.  Liver transaminase levels should be evaluated prior to initiation of therapy, every 6 to 12 weeks for the first year, and periodically thereafter (e.g., semiannually).  Patients who develop elevated  ALT or AST levels during therapy should be monitored until abnormalities resolve.  If an increase above 3 times the upper limit of normal persists, therapy should be withdrawn.  Liver biopsy should be considered in patients with elevations that persist beyond cessation of therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1327, 0, 'Niacin', 'Hypotension', 'The use of niacin and niacinamide (nicotinamide) is contraindicated in patients with severe hypotension.  These agents have peripheral vasodilating effects and may commonly cause flushing at dosages substantially exceeding those for physiologic requirements (e.g., lipid-lowering dosages).', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1328, 0, 'Niacin', 'Peptic Ulcer', 'The use of niacin and niacinamide (nicotinamide) at dosages substantially exceeding those for physiologic requirements is contraindicated in patients with active peptic ulcer disease.  These agents have been reported to activate peptic ulcer.  Treatment using pharmacologic dosages (e.g., lipid-lowering dosages) should be administered cautiously in patients with a history of peptic ulcer disease.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1329, 0, 'Niacin', 'Hyperglycemia', 'Elevated fasting blood sugars and decreased glucose tolerance have been reported during niacin and niacinamide (nicotinamide) therapy at dosages substantially exceeding those for physiologic requirements.  Patients with diabetes mellitus should be monitored more closely during therapy with these agents, and adjustments made accordingly in their antidiabetic regimen.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1330, 0, 'Niacin', 'Hyperuricemia', 'Large doses of niacin and niacinamide (nicotinamide) can compete with uric acid for excretion by the kidney.  Hyperuricemia and precipitation of gout have been reported during long-term therapy.  Treatment using pharmacologic dosages (e.g., lipid-lowering dosages) of these agents should be administered cautiously in patients with or predisposed to gout.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1331, 0, 'Nicardipine', 'Aortic Valve Stenosis', 'The use of some calcium channel blockers (CCBs) is contraindicated in patients with advanced aortic stenosis.  CCBs whose pharmacologic effect is partially dependent on their ability to reduce afterload (e.g., diltiazem, nicardipine, nifedipine, verapamil) may be of less benefit in these patients due to a fixed impedance to flow across the aortic valve and may, in fact, worsen rather than improve myocardial oxygen balance.  Rarely, heart failure has developed following the initiation of these CCBs, particularly in patients receiving concomitant beta-blocker therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1332, 0, 'Nicardipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1333, 0, 'Nicardipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1334, 0, 'Nicardipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1335, 0, 'Nicardipine', 'Kidney Diseases', 'The systemic clearance of nicardipine has been shown to decrease in patients with renal impairment.  Mean plasma concentrations were approximately two-fold higher than in healthy controls.  Therapy with nicardipine should be administered cautiously in patients with impaired renal function.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1336, 0, 'Nicardipine', 'Heart Failure', 'Calcium channel blockers (CCBs) may have varying degrees of negative inotropic effect.  Congestive heart failure (CHF), worsening of CHF, and pulmonary edema have occurred in some patients treated with a CCB, primarily verapamil.  Some CCBs have also caused mild to moderate peripheral edema due to localized vasodilation of dependent arterioles and small blood vessels, which can be confused with the effects of increasing left ventricular dysfunction.  Although some CCBs have been used in the treatment of CHF, therapy with CCBs should be administered cautiously in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, caution is advised in patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened by administration of a CCB.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1337, 0, 'Nilotinib', 'Pancreatitis', 'Nilotinib can cause increases in serum lipase.  Patients with a previous history of pancreatitis might be at increased risk and should be monitored carefully for lipase elevations and any abdominal symptoms.  Serum lipase should be monitored monthly or as clinically indicated and treatment might need to be interrupted until pancreatitis is excluded as a diagnosis.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1338, 0, 'Nilotinib', 'Long QT Syndrome', 'Nilotinib should not be used in patients with hypokalemia, hypomagnesemia or long QT syndrome, as it has shown to prolong QT interval in a concentration-dependent manner.  This can cause a ventricular tachycardia called Torsade de Pointes which can result in syncope, seizures, and/or death.  Before initiating nilotinib, electrolytes should be tested.  Hypokalemia or hypomagnesemia should be corrected before starting treatment and monitored periodically.  Patients at risk should be monitored with an EKG before and during treatment as clinically indicated and dose adjustments might be needed.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1339, 0, 'Nilotinib', 'Cardiovascular Diseases', 'Cardiovascular events, including arterial vascular occlusive events, peripheral arterial occlusive events and ischemic cerebrovascular events have been reported in patients receiving tyrosine kinase inhibitors.  If acute signs or symptoms of cardiovascular events occur, patients should seek immediate medical attention.  The cardiovascular status and risk factors of patients should be evaluated prior to therapy and cardiovascular monitoring and management should take place during treatment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1340, 0, 'Nilotinib', 'Water-Electrolyte Imbalance', 'Fluid retention occurs with BCR-ABL tyrosine kinase inhibitors therapy and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema.  Caution should be taken when using these drugs in patients with preexisting fluid retention or congestive heart failure.  Monitor and manage patients using standards of care.  Interrupt, reduce dose or discontinue therapy as necessary.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1341, 0, 'Nilotinib', 'Bone Marrow Failure Disorders', 'Thrombocytopenia, aplastic anemia, agranulocytosis and neutropenia occur with BCR-ABL tyrosine kinase inhibitors.  Therapy with these drugs should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed every 1-2 weeks for the first month of therapy and then monthly thereafter, or as clinically indicated.  To manage myelosuppression, withhold, reduce dose, or discontinue therapy as necessary.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1342, 0, 'Nilotinib', 'Hepatic Insufficiency', 'Nilotinib exposure is increased in patients with hepatic impairment.  The use of a lower starting dose might be needed.  Additionally, there have been reports of hepatotoxicity as measured by elevations in bilirubin, AST, ALT and alkaline phosphatase.  Liver function should be monitored before initiation of treatment and regularly during therapy.  Dose reduction or interruption might be needed if laboratory abnormalities are found.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1343, 0, 'Nilotinib', 'Lactose Intolerance', 'Nilotinib capsules contain lactose, so it is not recommended for patients with rare hereditary problems of galactose intolerance, severe lactase deficiency with a severe degree of intolerance to lactose- containing products, or of glucose-galactose malabsorption.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1344, 0, 'Nintedanib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1345, 0, 'Nintedanib', 'Thromboembolism', 'Arterial thromboembolic events, including myocardial infarction have been reported in patients taking nintedanib.  It is recommended to exercise caution when treating patients at higher cardiovascular risk, including known coronary artery disease and to consider treatment interruption in patients who develop signs or symptoms of acute myocardial ischemia.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1346, 0, 'Nintedanib', 'Hemorrhage', 'Nintedanib may increase the risk of bleeding.  Nintedanib should only be used in patients with known risk of bleeding if the anticipated benefit outweighs the potential risk.  Close monitoring is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1347, 0, 'Nintedanib', 'Peptic Ulcer Perforation', 'Nintedanib may increase the risk of gastrointestinal perforation.  Use caution when treating patients who have had recent abdominal surgery.  It is recommended to discontinue therapy with nintedanib in patients who develop gastrointestinal perforation.  Nintedanib should only be used in patients with known risk of gastrointestinal perforation if the anticipated benefit outweighs the potential risk.  Care and close monitoring is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1348, 0, 'Nintedanib', 'Hepatic Insufficiency', 'The use of nintedanib is associated with elevations of liver enzymes.  Treatment with nintedanib is not recommended in patients with moderate or severe hepatic impairment.  Patients with mild hepatic impairment can be treated with a reduced dose of nintedanib.  It is recommended to conduct liver function tests prior to treatment with nintedanib and periodically thereafter as clinically indicated.  Dosage modifications or interruption may be necessary for liver enzyme elevations as clinically indicated and according to medical practices.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1349, 0, 'Nintedanib', 'Kidney Diseases', 'Based on a population pharmacokinetics analysis of nintedanib, exposure to nintedanib is not influenced by mild or moderate renal impairment.  No dose adjustment is required in patients with mild to moderate renal impairment.  Care and close monitoring is recommended when using this agent in patients with severe renal impairment and end-stage renal disease as the safety, efficacy, and, pharmacokinetics of nintedanib have not been studied these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1350, 0, 'Atenolol', 'Diseases requiring hemodialysis', 'Atenolol is moderately removed by conventional hemodialysis.  Patients on hemodialysis should receive a dose of atenolol following each dialysis session when they are hemodynamically stable to avoid marked falls in blood pressure.  The hemodynamic status should be closely monitored before and after the dose.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1351, 0, 'Atenolol', 'Kidney Diseases', 'Atenolol is eliminated by the kidney.  Significant accumulation of the drug occurs in patients with a creatinine clearance below 35 mL/min/1.73 m2.  Dosage adjustments are recommended for these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1352, 0, 'Atenolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1353, 0, 'Atenolol', 'Shock, Cardiogenic', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with hypotension or cardiogenic shock.  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to further depress cardiac output and blood pressure, which can be detrimental in these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1354, 0, 'Atenolol', 'Heart Failure', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with overt congestive heart failure (CHF).  Sympathetic stimulation may be important in maintaining the hemodynamic function in these patients, thus beta-blockade can worsen the heart failure.  However, therapy with beta-blockers may be beneficial and can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Carvedilol, specifically, is indicated for use with these agents in the treatment of mild to severe heart failure of ischemic or cardiomyopathic origin.  There is also increasing evidence that the addition of a beta-blocker to standard therapy can improve morbidity and mortality in patients with advanced heart failure, although it is uncertain whether effectiveness varies significantly with the different agents.  Data from one meta-analysis study suggest a greater reduction of mortality risk for nonselective beta-blockers than for beta-1 selective agents.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1355, 0, 'Atenolol', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since cardioselectivity is not absolute, larger doses of beta-1 selective agents may demonstrate these effects as well.  Therapy with beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1356, 0, 'Atenolol', 'Hypersensitivity', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1357, 0, 'Atenolol', 'Myocardial Ischemia', 'Heightened sensitivity to catecholamines may occur after prolonged use of beta-adrenergic receptor blocking agents (aka beta-blockers).  Exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following abrupt withdrawal of therapy.  Cessation of beta-blocker therapy, whenever necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks in patients with coronary insufficiency.  Patients should be advised not to discontinue treatment without first consulting with the physician.  In patients who experience an exacerbation of angina following discontinuation of beta-blocker therapy, the medication should generally be reinstituted, at least temporarily, along with other clinically appropriate measures.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1358, 0, 'Atenolol', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1359, 0, 'Atenolol', 'Cerebrovascular Disorders', 'Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1360, 0, 'Atenolol', 'Glaucoma', 'Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1361, 0, 'Atenolol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1362, 0, 'Atenolol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1363, 0, 'Atenolol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1364, 0, 'Atenolol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1365, 0, 'Atenolol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1366, 0, 'Atenolol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1367, 0, 'Atenolol', 'Asthma', 'Patients with bronchospastic disease, should, in general, not receive beta blockers, including cardioselective beta-blockers.  Because of the relative beta-1 selectivity, cardioselective beta-blockers may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment.  Because beta-1 selectivity is not absolute, the lowest possible dose of these agents should be used.  Consider administering in smaller doses to avoid the higher plasma levels associated with the longer dosing intervals.  If dosage must be increased, dividing the dose should be considered to achieve lower peak blood levels.  It is recommended to have bronchodilators, including beta-2 agonists, readily available or administered concomitantly if necessary.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1368, 0, 'Nilutamide', 'Liver Diseases', 'The use of nilutamide is contraindicated in patients with severe hepatic impairment.  Patients with hepatic dysfunction may be at increased risk for nilutamide- associated hepatitis and marked increases in liver enzymes.  Nilutamide is extensively metabolized by the liver and the metabolic activity and disposition of nilutamide may be altered in patients with severe hepatic impairment.   Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Clinical monitoring of hepatic function is recommended and nilutamide should be discontinued if liver transaminase levels increase two to three times the upper limit of normal.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1369, 0, 'Nilutamide', 'Lung Diseases, Interstitial', 'The use of nilutamide is contraindicated in patients with severe respiratory impairment.  Patients with pulmonary dysfunction may be at increased risk for nilutamide- associated interstitial pneumonitis.  Patients should be instructed to immediately report any signs or symptoms of respiratory impairment such as dyspnea, cough, chest pain, or fever.  Clinical monitoring of pulmonary function, including pre-treatment chest X-ray, is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1370, 0, 'Nicotine', 'Cardiovascular Diseases', 'Nicotine has dose-dependent cardiovascular effects.  At dosages used for smoking cessation, nicotine may produce peripheral vasoconstriction and increase heart rate, myocardial contractility and blood pressure.  Although these effects are relatively minor and clinically insignificant in most healthy individuals, complications may occasionally occur in patients with underlying cardiovascular disease, particularly if they continue to smoke during nicotine therapy.  Therapy with nicotine should be administered cautiously in patients with coronary artery disease, cardiac arrhythmias, and peripheral vascular disease.  In general, nicotine therapy should be avoided during the immediate postmyocardial infarction period, in severe or worsening angina, and in life-threatening arrhythmias.  All patients should stop smoking completely during nicotine replacement therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1371, 0, 'Nicotine', 'Pheochromocytoma', 'Nicotine causes the release of catecholamines from the adrenal medulla.  Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas.  Therapy with nicotine should be administered cautiously in patients with these tumors.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1372, 0, 'Nicotine', 'Diabetes Mellitus', 'Nicotine causes the release of catecholamines from the adrenal medulla, which can stimulate glycogenolysis.  Patients with diabetes mellitus should be monitored more closely during therapy with nicotine, and their antidiabetic regimen adjusted accordingly.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1373, 0, 'Nicotine', 'Hyperthyroidism', 'Nicotine causes the release of catecholamines from the adrenal medulla, which can exacerbate the sympathetic nervous system manifestations of hyperthyroidism such as tachycardia, angina, and heart failure.  Therapy with nicotine should be administered cautiously in patients with hyperthyroidism.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1374, 0, 'Nicotine', 'Liver Diseases', 'Nicotine is primarily metabolized by the liver, and systemic clearance is dependent on liver blood flow.  Although data are lacking, impairment of liver function is likely to reduce nicotine clearance to some extent.  Patients with liver disease using a nicotine product should be monitored for development of undue adverse effects and signs of nicotine toxicity, including nausea, salivation, cold sweat, palpitation, abdominal pain, diarrhea, headache, dizziness, vomiting, auditory and vision disturbances, tremors, mental confusion, and weakness.  If necessary, nicotine dosage should be reduced or the treatment discontinued.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1375, 0, 'Nicotine', 'Peptic Ulcer', 'Nicotine can delay healing in peptic ulcer disease.  Therapy with nicotine should be administered cautiously in patients with peptic ulcers.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1376, 0, 'Nisoldipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1377, 0, 'Nisoldipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1378, 0, 'Nisoldipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1379, 0, 'Nisoldipine', 'Heart Failure', 'Calcium channel blockers (CCBs) may have varying degrees of negative inotropic effect.  Congestive heart failure (CHF), worsening of CHF, and pulmonary edema have occurred in some patients treated with a CCB, primarily verapamil.  Some CCBs have also caused mild to moderate peripheral edema due to localized vasodilation of dependent arterioles and small blood vessels, which can be confused with the effects of increasing left ventricular dysfunction.  Although some CCBs have been used in the treatment of CHF, therapy with CCBs should be administered cautiously in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, caution is advised in patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened by administration of a CCB.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1380, 0, 'Nitrofurantoin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1381, 0, 'Nitrofurantoin', 'Glucosephosphate Dehydrogenase Deficiency', 'Hemolytic anemia has been reported in patients treated with nitrofurantoin, primarily in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  Therapy with nitrofurantoin should be avoided or administered cautiously in patients with G-6-PD deficiency.  The development of hemolysis is an indication for withdrawal of nitrofurantoin therapy.  Hemolysis ceases when the drug is withdrawn.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1382, 0, 'Nitrofurantoin', 'Liver Diseases', 'The use of nitrofurantoin has rarely been associated with hepatotoxicity, including hepatitis, cholestatic jaundice, chronic active hepatitis, and hepatic necrosis.  Nitrofurantoin macrocrystals capsules are contraindicated in patients with a previous history of cholestatic jaundice/hepatic dysfunction associated with nitrofurantoin.  Most acute reactions are self-limiting and resolve spontaneously, although fatalities have been reported.  Therapy with nitrofurantoin should be administered cautiously in patients with liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  The drug should be withdrawn immediately if hepatitis or liver damage occurs and is felt to be drug-related.  Since nitrofurantoin is partially metabolized by the liver, a reduced dosage may also be necessary to prevent toxicity.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1383, 0, 'Nitrofurantoin', 'Kidney Diseases', 'The use of nitrofurantoin is contraindicated in patients with anuria, oliguria, or significant renal impairment (CrCl < 60 mL/min).  Urinary concentration of the drug is likely to be inadequate in these patients, increasing the risk of therapeutic failure.  Since nitrofurantoin is eliminated by the kidney, risk of toxicity may also be increased.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1384, 0, 'Nitrofurantoin', 'Peripheral Nervous System Diseases', 'The use of nitrofurantoin has occasionally been associated with the development of peripheral neuropathy, which may be severe and irreversible.  Patients at risk include the elderly and those with renal impairment, anemia, diabetes mellitus, electrolyte imbalance, vitamin B12 deficiency, diabetes, and/or debilitating diseases.  Therapy with nitrofurantoin should be administered cautiously in patients with one or more risk factors and/or preexisting peripheral neuropathy.  Periodic monitoring of renal function is recommended during prolonged therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1385, 0, 'Nitrofurantoin', 'Respiratory Insufficiency', 'Chronic pulmonary reactions, generally in patients who have received continuous treatment for 6 months or longer have been reported with the use of nitrofurantoin.  Caution is recommended when prescribing this agent to patients with pulmonary dysfunction.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1386, 0, 'Nitroglycerin', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1387, 0, 'Nitroglycerin', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1388, 0, 'Nitroglycerin', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1389, 0, 'Nitroglycerin', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1390, 0, 'Nitroglycerin', 'Intracranial Hypertension', 'Organic nitrates and nitrites can increase cerebrospinal fluid pressure.  Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1391, 0, 'Nitroglycerin', 'Pericarditis', 'The use of intravenous nitroglycerin is contraindicated in patients with constrictive pericarditis, pericardial tamponade, or restrictive cardiomyopathy.  In these patients, cardiac output is dependent upon venous return, which can be reduced by nitroglycerin due to venous pooling.  Also, nitroglycerin-induced hypotension may lead to paradoxical bradycardia and increased angina pectoris.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1392, 0, 'Nitroglycerin', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1393, 0, 'Nitroglycerin', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1394, 0, 'Nitazoxanide', 'Diabetes Mellitus', 'Alinia (brand of nitazoxanide) oral suspension contains 1.48 grams of sucrose per 5 mL.  The sugar content should be considered when this product is used in patients with diabetes.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1395, 0, 'Nitazoxanide', 'Liver Diseases', 'The pharmacokinetics of nitazoxanide in patients with compromised renal and/or hepatic function have not been studied.  Therapy with nitazoxanide should be administered cautiously in patients with hepatic and biliary disease and/or renal disease.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1396, 0, 'Nitric Oxide', 'Heart Failure', 'Patients with left ventricular dysfunction treated with nitric oxide may experience pulmonary edema, increased pulmonary capillary wedge pressure, worsening of left ventricular dysfunction, systemic hypotension, bradycardia and cardiac arrest.  Patients should be monitored and therapy should be discontinued if symptoms arise and symptomatic care should be provided.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1397, 0, 'Niraparib', 'Cardiovascular disease', 'Niraparib has the potential to cause effects on pulse rate and blood pressure.  Hypertension and hypertensive crisis have been reported in patients treated with niraparib.  It is recommended to monitor blood pressure and heart rate monthly for the first year and periodically thereafter during treatment with niraparib.  Closely monitor patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.  Medically manage hypertension with antihypertensive medications and adjust the dose of niraparib as necessary.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1398, 0, 'Niraparib', 'Liver Diseases', 'No dose adjustment is needed in patients with mild hepatic impairment according to the National Cancer Institute - Organ Dysfunction Working Group (NCI-ODWG) criteria.  Caution is recommended in patients with moderate to severe hepatic impairment as the safety of niraparib has not been established in these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1399, 0, 'Niraparib', 'Myelodysplastic Syndromes', 'Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML), including cases with fatal outcome, have been reported with the use of niraparib.  It is recommended to use caution when using this agent in patients with MDS/AML, its use must be weighed against the risk.  Discontinue the use of niraparib in patients who develop MDS/AML.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1400, 0, 'Niraparib', 'Pancytopenia', 'Hematologic adverse reactions (thrombocytopenia, anemia and neutropenia) have been reported in patients treated with niraparib.  It is recommended to monitor complete blood counts weekly for the first month, monthly for the next eleven months of treatment, and periodically after this time.  Do not start niraparib until patients have recovered from hematological toxicity caused by previous chemotherapy (less than equal to Grade 1).  If hematological toxicities do not resolve within 28 days following interruption, discontinue niraparib, and refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1401, 0, 'Niraparib', 'Kidney Diseases', 'No dose adjustment is necessary for patients with mild to moderate renal impairment.  Caution is recommended in patients with severe renal impairment or end stage renal disease undergoing hemodialysis as the safety of niraparib has not been established in these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1402, 0, 'Nitisinone', 'Leukopenia', 'In clinical trials, patients treated with oral formulations of nitisinone and dietary restriction developed transient leukopenia (3%), thrombocytopenia (3%), or both (1.5%).  No patients developed infections or bleeding as a result of the episodes of leukopenia and thrombocytopenia.  Caution is advised especially in patients with low blood cell counts.  Platelet and white blood cell counts should be monitored during therapy with nitisinone.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1403, 0, 'Nifedipine', 'Aortic Valve Stenosis', 'The use of some calcium channel blockers (CCBs) is contraindicated in patients with advanced aortic stenosis.  CCBs whose pharmacologic effect is partially dependent on their ability to reduce afterload (e.g., diltiazem, nicardipine, nifedipine, verapamil) may be of less benefit in these patients due to a fixed impedance to flow across the aortic valve and may, in fact, worsen rather than improve myocardial oxygen balance.  Rarely, heart failure has developed following the initiation of these CCBs, particularly in patients receiving concomitant beta-blocker therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1404, 0, 'Nifedipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1405, 0, 'Nifedipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1406, 0, 'Nifedipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1407, 0, 'Nifedipine', 'Hypertension', 'For the long-term treatment of hypertension, only the extended-release formulations of nifedipine should be used.  The US National Heart, Lung, and Blood Institute and the FDA Cardiovascular and Renal Drug Advisory Committee have issued warnings against the use of immediate-release nifedipine for this purpose based on review of three epidemiologic studies of patients with hypertension and unstable angina who were treated with calcium channel blockers (CCBs) and at least two meta-analyses of randomized, controlled trials that included patients receiving CCBs.  Two of the case-control studies found an increased risk of myocardial infarction (MI) in patients taking immediate-release nifedipine, although the third did not.
The use of immediate-release nifedipine (orally or sublingually) is also contraindicated for acute reduction of blood pressure.  Profound hypotension, acute myocardial infarction, and deaths have been reported when nifedipine was used in this manner.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1408, 0, 'Nifedipine', 'Myocardial Infarction', 'Clinical trials studying the use of immediate-release nifedipine in patients who had just sustained myocardial infarctions have not demonstrated any benefit.  In fact, in some trials, patients who received immediate-release nifedipine had significantly worse outcomes than patients who received placebo.  The manufacturers state that immediate-release formulations of nifedipine should not be administered for 1 week after myocardial infarction.  They should also be avoided in the setting of acute coronary syndrome, when infarction may be imminent.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1409, 0, 'Nifedipine', 'Heart Failure', 'Calcium channel blockers (CCBs) may have varying degrees of negative inotropic effect.  Congestive heart failure (CHF), worsening of CHF, and pulmonary edema have occurred in some patients treated with a CCB, primarily verapamil.  Some CCBs have also caused mild to moderate peripheral edema due to localized vasodilation of dependent arterioles and small blood vessels, which can be confused with the effects of increasing left ventricular dysfunction.  Although some CCBs have been used in the treatment of CHF, therapy with CCBs should be administered cautiously in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, caution is advised in patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened by administration of a CCB.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1410, 0, 'Nifedipine', 'Kidney Diseases', 'Although the clearance of nifedipine is not dependent on renal function, use of the drug in patients with uremia has been associated with enhanced pharmacologic effects, possibly due to increased sensitivity to the drug or reduced protein binding.  Rarely, reversible elevations in BUN and serum creatinine have been reported in patients with preexisting chronic renal insufficiency given nifedipine, although a causal relationship has not been established.  Nephritis and renal failure have also been observed.  Therapy with nifedipine should be administered cautiously in patients with significantly impaired renal function.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1411, 0, 'Nifedipine', 'Intestinal Obstruction', 'The extended-release formulation of nifedipine (Procardia XL) contains a non-deformable material.  There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products.  Therapy with the extended-release formulation of nifedipine should be administered cautiously in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1412, 0, 'Nifurtimox', 'Alcoholism', 'The consumption of alcohol is contraindicated when receiving treatment with nifurtimox as it may increase the incidence and severity of adverse events.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1413, 0, 'Nifurtimox', 'Liver Diseases', 'The effect of hepatic impairment on the pharmacokinetics of nifurtimox is unknown.  Administer under close medical supervision on these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1414, 0, 'Nifurtimox', 'Nervous System Diseases', 'Patients with a history of brain injury, seizures, psychiatric disease or behavioral alterations may experience worsening of their conditions when receiving treatment with nifurtimox.  This drug should be administered under close medical supervision in these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1415, 0, 'Nifurtimox', 'Porphyrias', 'Treatment with nifurtimox may precipitate attacks of porphyria and should be used under close medical supervision in patients with this diagnosis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1416, 0, 'Nifurtimox', 'Kidney Diseases', 'The effect of renal impairment on the pharmacokinetics of nifurtimox is unknown, but studies suggest that the blood concentrations of the drug are increased in patients with end-stage renal disease that require hemodialysis.  Administer under close medical supervision on these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1417, 0, 'Nitroprusside', 'Cerebrovascular Disorders', 'The use of nitroprusside is contraindicated in patients with cerebral vascular insufficiency.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1418, 0, 'Nitroprusside', 'Hypertension', 'Nitroprusside should not be used for the treatment of compensatory hypertension, such as that associated with aortic coarctation or arteriovenous shunt.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1419, 0, 'Nitroprusside', 'Optic Atrophy, Hereditary, Leber', 'The use of nitroprusside is contraindicated in patients with defective or absent rhodanase activity, such as patients with congenital (Leber''s) optic atrophy or with tobacco amblyopia.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1420, 0, 'Nitroprusside', 'Sepsis', 'Sodium nitroprusside should not be used for the treatment of acute congestive heart failure associated with reduced peripheral vascular resistance such as high- output heart failure that may be seen in endotoxic sepsis.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1421, 0, 'Nitroprusside', 'Anemia', 'When sodium nitroprusside is used to control hypotension during anesthesia, the patient''s capacity to compensate for anemia and hypovolemia may be diminished.  If possible, preexisting anemia and hypovolemia should be corrected prior to administration of sodium nitroprusside.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1422, 0, 'Nitroprusside', 'Hepatic Insufficiency', 'Use caution when administering sodium nitroprusside to patients with hepatic insufficiency.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1423, 0, 'Nitroprusside', 'Intracranial Hypertension', 'Like other vasodilators, sodium nitroprusside can cause increases in intracranial pressure.  In patients whose intracranial pressure is already elevated, sodium nitroprusside should be used only with extreme caution.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1424, 0, 'Nitrous acid', 'Methemoglobinemia', 'Sodium nitrite causes hypotension and methemoglobin formation, which diminishes oxygen carrying capacity.  Hypotension and methemoglobin formation can occur concurrently or separately.  Sodium nitrite should be used to treat acute life-threatening cyanide poisoning but be used with caution in patients where the diagnosis of cyanide poisoning is uncertain.  Patients should be closely monitored to ensure adequate perfusion and oxygenation during treatment with sodium nitrite.  Alternative therapeutic approaches should be considered in patients known to have diminished oxygen or cardiovascular reserve (e.g., smoke inhalation victims, preexisting anemia, cardiac or respiratory compromise), and those at higher risk of developing methemoglobinemia (e.g., congenital methemoglobin reductase deficiency) as they are at greater risk for potentially life-threatening adverse events related to the use of sodium nitrite.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1425, 0, 'Nitrous acid', 'Renal Insufficiency', 'Sodium nitrite is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.  Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1426, 0, 'Atazanavir', 'Heart Block', 'Atazanavir may prolong the PR interval of the electrocardiogram in some patients.  In one study, the mean maximum change in PR interval from baseline was 24 msec following a 400 mg oral dose of atazanavir versus 13 msec following placebo dosing.  In studies of healthy volunteers and HIV patients, abnormalities in atrioventricular (AV) conduction were asymptomatic and limited to first-degree AV block.  Rarely, second-degree AV block and other conduction abnormalities have occurred in overdose.  Due to limited clinical experience, therapy with atazanavir should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block).', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1427, 0, 'Atazanavir', 'Nephrolithiasis', 'Cases of nephrolithiasis, some of which resulted in acute interstitial nephritis, renal failure, and/or hospitalization, have been reported during postmarketing surveillance in HIV-infected patients receiving atazanavir therapy.  Because these events were reported voluntarily during clinical practice, estimates of frequency cannot be made.  The median time between atazanavir initiation and the onset of nephrolithiasis was 1.7 years, with a range of 5 weeks to 6 years.  Therapy with atazanavir should be administered cautiously in patients with a current or past history of nephrolithiasis, as well as possible risk factors such as renal and/or hepatic insufficiency.  Adequate hydration and/or urine acidification may help reduce the risk.  However, urine acidification may be poorly tolerated and possibly harmful, particularly in patients receiving concomitant treatment with sulfonamide antibiotics.  Patients who are dehydrated may also be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluids if necessary.  Patients should be instructed to seek medical attention if they experience potential signs and symptoms of nephrolithiasis/urolithiasis such as flank pain, hematuria, dysuria, anuria, and urinary urgency.  Temporary interruption or discontinuation of therapy may be required.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1428, 0, 'Atazanavir', 'Kidney Diseases', 'Atazanavir is not recommended for use in HIV- treatment experienced patients with end stage renal disease managed with hemodialysis.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1429, 0, 'Atazanavir', 'Hemophilia A', 'There have been postmarketing reports of increased bleeding, including spontaneous skin hematomas and hemarthrosis, in types A and B hemophiliac patients treated with protease inhibitors.  However, a causal relationship has not been established.  In some patients, additional Factor VIII was given.  In more than half of the reported cases, protease inhibitor therapy was continued or reintroduced following an interruption.  Hemophiliacs and patients with other coagulation defects should be monitored closely for bleeding during protease inhibitor therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1430, 0, 'Atazanavir', 'Liver Diseases', 'Patients with underlying hepatitis B or C viral infections or marked elevations in transaminases prior to atazanavir treatment may be at increased risk for developing further transaminase elevations or hepatic decompensation during use of atazanavir.  In addition, atazanavir is primarily metabolized by the liver and may accumulate in patients with moderate or severe hepatic impairment.  Therapy with atazanavir should be administered cautiously in patients with preexisting liver disease, liver enzyme abnormalities, or hepatitis.  Atazanavir is not recommended for use in patients with severe hepatic impairment, and the combination of atazanavir/ritonavir is not recommended for patients with any degree of hepatic impairment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1431, 0, 'Atazanavir', 'Phenylketonurias', 'Atazanavir oral powder (Reyataz) contains phenylalanine (a component of aspartame) which can be harmful to patients with phenylketonuria (PKE).  Each packet contains 35 mg of phenylalanine.  Atazanavir in capsules (Reyataz) does not contain phenylalanine.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1432, 0, 'Atazanavir', 'Hyperglycemia', 'New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, glucose intolerance, hyperglycemia, and some cases of diabetic ketoacidosis have been reported during postmarketing surveillance in HIV-infected patients treated with protease inhibitors (PIs).  In some cases, glucose abnormalities/hyperglycemia persisted despite discontinuation of PI therapy.  Frequently, insulin resistance may accompany fat redistribution and serum lipid elevations in what is collectively termed the HIV-associated lipodystrophy syndrome.  Although a causal relationship has not been established, these metabolic disturbances have most often occurred in HIV-infected patients during treatment with potent antiretroviral regimens containing PIs.  Monitoring patients for hyperglycemia, new onset diabetes mellitus, or exacerbation of diabetes mellitus should be considered during PI therapy.  Dosage adjustments in insulin or oral hypoglycemic medications may be necessary in patients with diabetes.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1433, 0, 'Atazanavir', 'Hyperlipidemias', 'Hyperlipidemia has been observed in 10% of patients receiving ritonavir during clinical trials.  Increases of 30% to 40% from baseline have been reported for total cholesterol and 200% to 300% or more for triglycerides.  These effects have also been reported during postmarketing experience with other protease inhibitors (PIs) but may be the most dramatic with ritonavir.  The clinical significance of these elevations is unclear.  Severe hyperlipidemia is known to sometimes cause pancreatitis.  In addition, some patients have reportedly developed symptomatic atherosclerosis and coronary artery disease after initiating PI treatment.  Patients with preexisting hyperlipidemia may require closer monitoring during PI therapy, and adjustments made accordingly in their lipid-lowering regimen.  PI therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1434, 0, 'Atezolizumab', 'Endocrine System Diseases', 'Immune-related thyroid disorders, adrenal insufficiency, and type 1 diabetes mellitus, including diabetic ketoacidosis, have been reported in patients receiving atezolizumab.  It is recommended to monitor patients for clinical signs and symptoms of endocrinopathies and to institute appropriate measures as necessary.  Monitor as clinically indicated prior to and periodically during treatment and withhold, reduce dose, or discontinue therapy as necessary.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1435, 0, 'Atezolizumab', 'Hepatitis', 'Immune-mediated hepatitis occurred in patients receiving atezolizumab treatment with reported liver test abnormalities.  Monitor patients for liver function test and for symptoms of hepatitis.  Monitor bilirubin prior to and periodically during treatment.  Therapy with atezolizumab should be administered cautiously in these patients.  It is recommended to withhold atezolizumab for Grade 2 immune-mediated hepatitis and institute appropriate measures and to permanently discontinue therapy for Grade or 4 immune-mediated hepatitis', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1436, 0, 'Atezolizumab', 'Infections', 'Severe infections, including urinary tract infections, pneumonia, sepsis, herpes encephalitis, and mycobacterial infection leading to retroperitoneal hemorrhage occurred in patients treated with atezolizumab.  It is recommended to monitor patients for signs and symptoms of infection and to treat with antibiotics for suspected or confirmed bacterial infections.  Withhold therapy for greater than or equal to Grade 3 infections.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1437, 0, 'Atezolizumab', 'Meningitis', 'Immune-related meningoencephalitis has been reported with the use of atezolizumab therapy.  Monitor patients for clinical signs and symptoms of meningitis or encephalitis.  Permanently discontinue therapy for any grade of meningitis or encephalitis.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1438, 0, 'Atezolizumab', 'Peripheral Nervous System Diseases', 'Immune-related myasthenic syndrome/myasthenia gravis, Guillain-BarrÃ©, and ocular inflammatory toxicity have been reported with the use of atezolizumab therapy.  Monitor patients for symptoms of motor and sensory neuropathy.  Permanently discontinue therapy for any grade of myasthenic syndrome/myasthenia gravis or Guillain-BarrÃ© syndrome and institute medical intervention as appropriate.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1439, 0, 'Atezolizumab', 'Pancreatitis', 'Immune-related pancreatitis, including increases in serum amylase and lipase levels have been reported with the use of atezolizumab therapy.  Caution is recommended and patients should be monitored for signs and symptoms of acute pancreatitis.  Withhold atezolizumab for greater than or equal to Grade 3 serum amylase or lipase levels (> 2.0 ULN), or Grade 2 or 3 pancreatitis and permanently discontinue therapy for Grade 4 or any grade of recurrent pancreatitis.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1440, 0, 'Atezolizumab', 'Colitis', 'Immune-mediated colitis or diarrhea have been reported during atezolizumab therapy, in some cases with fatal outcomes.  Monitor patients for signs and symptoms of diarrhea or colitis.  It is recommended to withhold treatment with atezolizumab for Grade 2 diarrhea or colitis and if symptoms persist for longer than 5 days or recur, it is recommended to administer 1 to 2 mg/kg prednisone or equivalent per day.  Withhold treatment for Grade 3 diarrhea or colitis and treat with IV methylprednisolone 1 to 2 mg/kg per day and convert to oral steroids once the patient has improved.  For both Grade 2 and Grade 3 diarrhea or colitis, when symptoms improve to Grade 0 or Grade 1, taper steroids over greater than or equal to 1 month.  Resume treatment if the event improves to Grade 0 or 1 within 12 weeks and corticosteroids have been reduced to the equivalent of less than or equal to 10 mg oral prednisone per day.  Permanently discontinue atezolizumab for Grade 4 diarrhea or colitis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1441, 0, 'Atezolizumab', 'Liver Diseases', 'Population pharmacokinetic analyses suggest that no dose adjustment of atezolizumab is needed for patients with mild hepatic impairment.  No clinical studies were conducted with atezolizumab in patients with moderate or severe hepatic impairment.  Caution is recommended when using this agent.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1442, 0, 'Atezolizumab', 'Pneumonia', 'Immune-mediated pneumonitis, sometimes fatal, or interstitial lung disease have been reported during atezolizumab therapy.  Patients should be monitored with radiographic imaging and for symptoms of pneumonitis.  Therapy with atezolizumab should be administered cautiously in patients with or predisposed to pulmonary dysfunction.  It is recommended to withhold atezolizumab until resolution for Grade 2 pneumonitis and to permanently discontinue therapy for Grade 3 or 4 pneumonitis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1443, 0, 'Atezolizumab', 'Kidney Diseases', 'Population pharmacokinetic analyses suggest that no dose adjustment of atezolizumab is required for patients with renal impairment.  The effect of severe renal impairment on the pharmacokinetics of atezolizumab is unknown.  Caution is recommended with these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1444, 0, 'Nivolumab', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1445, 0, 'Nivolumab', 'Cardiovascular Diseases', 'The use of monoclonal antibodies administered via IV infusion may cause serious infusion reactions, including bronchospasm, hypoxia, dyspnea, fluctuations in blood pressure, laryngeal edema and pulmonary edema.  Caution should be taken in patients with a history of cardiopulmonary disease as they may require additional post-infusion medications to manage respiratory complications.  It is recommended to administer required intravenous hydration and premedication with antihistamines, analgesics, and antipyretics before administration.  Monitor closely for signs and symptoms of infusion reactions during and for at least 4 hours following completion of each infusion in a setting where cardiopulmonary resuscitation medication and equipment are available.  Immediately interrupt or permanently discontinue treatment and institute supportive management for severe or prolonged infusion reactions as appropriate.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1446, 0, 'Nivolumab', 'Tumor Lysis Syndrome', 'Tumor lysis syndrome (TLS) has occurred in patients receiving certain monoclonal antibodies.  Patients with high tumor burden and those with high circulating lymphocyte counts of greater than 25 X 10^9/L have a higher risk of developing TLS.  Consider tumor lysis prophylaxis prior to the infusion with anti-hyperuricemics and hydration beginning 12 to 24 hours prior to infusion.  It is recommended to correct electrolytes abnormalities, and monitor renal function in patients who develop TLS.  Monitor for signs and symptoms of TLS and temporary interruption or discontinuation of therapy might be required.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1447, 0, 'Nivolumab', 'Colitis', 'Immune-mediated colitis has been reported with the use of nivolumab.  Monitor patients for signs and symptoms of colitis.  It is recommended to administer corticosteroids at a dose of 1 to 2 mg/kg/day prednisone equivalents followed by corticosteroid taper for severe or life-threatening colitis.  Administer corticosteroids at a dose of 0.5 to 1 mg/kg/day prednisone equivalents followed by corticosteroid taper for moderate colitis of more than 5 days duration; if worsening or no improvement occurs despite initiation of corticosteroids, increase dose to 1 to 2 mg/kg/day prednisone equivalents.  If appropriate modify the dose according to manufacturer recommendations when nivolumab is administered in combination with ipilimumab, and if nivolumab is withheld, ipilimumab should also be withheld.  Permanently discontinue nivolumab and ipilimumab for life-threatening or for recurrent colitis.  Care should be taken when using nivolumab in patients with inflammatory bowel disease.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1448, 0, 'Nivolumab', 'Diabetes Mellitus', 'Nivolumab can cause type 1 diabetes mellitus.  Monitor for hyperglycemia or other signs and symptoms of diabetes.  Withhold treatment in cases of severe hyperglycemia until metabolic control is achieved.  Permanently discontinue nivolumab for life-threatening hyperglycemia.  If appropriate modify the dose according to manufacturer recommendations when nivolumab is administered in combination with ipilimumab, and if nivolumab is withheld, ipilimumab should also be withheld.  Care should be exercised when using nivolumab in diabetic patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1449, 0, 'Nivolumab', 'Hepatic Insufficiency', 'Nivolumab can cause immune-mediated hepatitis.  Based on a population pharmacokinetic analysis, no dose adjustment is recommended for patients with mild or moderate hepatic impairment.  Caution is recommended when using nivolumab in patients with severe hepatic impairment as this agent has not been studied in these patients.  Monitor patients for abnormal liver tests prior to and periodically during treatment.  It is recommended to administer corticosteroids at a dose of 1 to 2 mg/kg/day prednisone equivalents followed by corticosteroid taper for severe or life-threatening transaminase elevations, with or without concomitant elevation in total bilirubin.  Administer corticosteroids at a dose of 0.5 to 1 mg/kg/day prednisone equivalents for moderate transaminase elevations.  If appropriate modify the dose according to manufacturer recommendations when nivolumab is administered in combination with ipilimumab, and if nivolumab is withheld, ipilimumab should also be withheld.  Care should be taken when using nivolumab in patients with liver disease.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1450, 0, 'Nivolumab', 'Nervous System Diseases', 'Nivolumab can cause immune-mediated encephalitis with no clear alternate etiology.  It is recommended to evaluate patients with neurologic symptoms with consultation with a neurologist, brain MRI, lumbar puncture, and as clinically indicated.  Withhold nivolumab in patients with new-onset moderate to severe neurologic signs or symptoms and evaluate to rule out infectious or other causes of moderate to severe neurologic deterioration.  If other etiologies are ruled out, administer corticosteroids at a dose of 1 to 2 mg/kg/day prednisone equivalents for patients with immune-mediated encephalitis, followed by corticosteroid taper.  Permanently discontinue nivolumab for immune-mediated encephalitis.  If appropriate modify the dose according to manufacturer recommendations when nivolumab is administered in combination with ipilimumab, and if nivolumab is withheld, ipilimumab should also be withheld.  Care should be taken when using nivolumab in patients with neurologic disorders.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1451, 0, 'Nivolumab', 'Pneumonia', 'Immune-mediated pneumonitis, including fatal cases have been reported with the use of nivolumab.  Monitor patients for signs with radiographic imaging and for symptoms of pneumonitis.  It is recommended to administer corticosteroids at a dose of 1 to 2 mg/kg/day prednisone equivalents for moderate or more severe pneumonitis, followed by corticosteroid taper.  Permanently discontinue therapy for severe or life-threatening pneumonitis and withhold therapy until resolution for moderate pneumonitis.  If appropriate modify the dose according to manufacturer recommendations when nivolumab is administered in combination with ipilimumab, and if nivolumab is withheld, ipilimumab should also be withheld.  Care should be taken when using nivolumab in patients with pulmonary infections.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1452, 0, 'Nivolumab', 'Kidney Diseases', 'Nivolumab can cause immune-mediated nephritis.  Monitor patients for elevated serum creatinine prior to and periodically during treatment.  It is recommended to administer corticosteroids at a dose of 1 to 2 mg/kg/day prednisone equivalents followed by corticosteroid taper for life-threatening increased serum creatinine.  Administer corticosteroids at a dose of 0.5 to 1 mg/kg/day prednisone equivalents for moderate or severe increased serum creatinine, if worsening or no improvement occurs, increase dose of corticosteroids to 1 to 2 mg/kg/day prednisone equivalents.  Withhold nivolumab for moderate or severe increased serum creatinine.  Permanently discontinue nivolumab for life-threatening increased serum creatinine.  If appropriate modify the dose according to manufacturer recommendations when nivolumab is administered in combination with ipilimumab, and if nivolumab is withheld, ipilimumab should also be withheld.  Care should be taken when using nivolumab in patients with renal dysfunction.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1453, 0, 'Nivolumab', 'Thyroid Diseases', 'Nivolumab can cause autoimmune thyroid disorders.  Monitor thyroid function prior to and periodically during treatment.  Administer hormone-replacement therapy for hypothyroidism.  Initiate medical management for control of hyperthyroidism.  There are no recommended dose adjustments of nivolumab for hypothyroidism or hyperthyroidism.  Care should be taken when using this agent in patients with thyroid disease.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1454, 0, 'Nivolumab', 'Myasthenia Gravis', 'Certain PD-1 inhibitors such as nivolumab and pembrolizumab should be used with caution in patients with myasthenia gravis (MG).  Worsening of myasthenic weakness has been reported in people with previously diagnosed MG.  It is recommended to advise patients with MG and cancer considering cancer immunotherapy about this possible side effect.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1455, 0, 'Norfloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1456, 0, 'Norfloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1457, 0, 'Norfloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1458, 0, 'Norfloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1459, 0, 'Norfloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1460, 0, 'Norfloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1461, 0, 'Norfloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1462, 0, 'Norfloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1463, 0, 'Norfloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1464, 0, 'Nizatidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1465, 0, 'Nizatidine', 'Kidney Diseases', 'Nizatidine and its metabolites are primarily eliminated by the kidney.  Although the drug is generally well-tolerated, the daily dosage should be reduced in patients with moderate to severe renal impairment (CrCl < 50 mL/min).', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1466, 0, 'Norethisterone', 'Abnormal Genital Bleeding', 'The use of contraceptives is contraindicated when there is an undiagnosed abnormal genital bleeding.  Adequate diagnostic measures should be undertaken to rule out the presence of any malignancy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1467, 0, 'Norethisterone', 'Liver Neoplasms', 'The use of oral contraceptives is contraindicated in patients with liver tumors.  An increased risk of benign hepatic adenomas and hepatocellular carcinomas has been associated with long-term, oral estrogen- progestin contraceptive use of at least 4 years and 8 years, respectively.  Although these tumors are rare and have not been reported with other types of estrogen or progestogen therapies, any preparation containing estrogens and/or progestogens should probably be avoided in patients with existing tumors of the liver.  Hepatic hemangiomas and nodular hyperplasia of the liver have been reported with isolated estrogen therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1468, 0, 'Norethisterone', 'Breast Neoplasms', 'The use of progestogens is considered by manufacturers to be contraindicated in patients with existing or suspected malignancy of the breast.  Some supportive data are available for medroxyprogesterone.  Specifically, medroxyprogesterone treatment may be associated with breast cancer, primarily when the drug is administered intramuscularly.  A pooled analysis of two case-control studies, one from the World Health Organization and the other from New Zealand, revealed a small overall relative risk of breast cancer in women who have ever used intramuscular medroxyprogesterone acetate.  The relative risk was higher in the subgroup of women who had initiated therapy within the previous 5 years.  Thus, an increased risk (approximately 2-fold) is associated with intramuscular medroxyprogesterone use in the first 5 years.  A more recent U.S. study also found a statistically significant increase in breast cancer risk among recent users (defined as last use within the past five years) who used depo-medroxyprogesterone acetate for 12 months or longer.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1469, 0, 'Norethisterone', 'Liver Diseases', 'The use of progestogens, in general, is contraindicated in patients with impaired hepatic function or liver disease.  There are little or no data concerning the pharmacokinetic disposition of the different progestogens in patients with hepatic disease.  However, most hormones, including progestational hormones, are known to be extensively metabolized by the liver.  Medroxyprogesterone should not be used by women with significant liver disease and should be discontinued if jaundice or disturbances of liver function occur.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1470, 0, 'Norethisterone', 'Thromboembolism', 'The use of progestogens, in general, is considered by manufacturers to be contraindicated in patients with active thrombophlebitis, cerebrovascular disease, or a current or past history of thromboembolic disorders.  While the role of progestogens in the development of thromboembolic events associated with hormonal therapy is often unclear and thought to be secondary to that of estrogens, it may not be insignificant.  Medroxyprogesterone, a common progestational agent, has been shown to produce a hypercoagulable state in high dosages.  Whether or not this effect contributes to the development of thrombotic events is unknown.  However, thrombophlebitis and pulmonary embolism have been reported with megestrol, an antineoplastic and progestational agent.  In addition, an increased risk of nonfatal venous thrombosis has been associated with oral contraceptive combinations containing desogestrel or gestodene relative to those that contain other progestins (e.g., levonorgestrel, norethindrone), suggesting some degree of hemostatic effect by progestogens.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1471, 0, 'Norethisterone', 'Depressive Disorder', 'The use of oral contraceptives has been associated with an increased incidence of depression.  It is uncertain whether this effect is related to the estrogenic or the progestogenic component of the contraceptive, although excess progesterone activity is associated with depression.  Patients with a history of depression receiving estrogen and/or progestogen therapy should be followed closely.  The manufacturer of medroxyprogesterone recommends monitoring patients who have a history of depression and to not re- administer medroxyprogesterone if depression recurs.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1472, 0, 'Norethisterone', 'Water-Electrolyte Imbalance', 'Estrogens and progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with excess fluid.  In addition, patients with conditions that may be adversely affected by fluid accumulation, such as asthma, epilepsy, migraine, and cardiovascular or renal dysfunction, should be observed for exacerbation of their condition during estrogen and/or progestogen therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1473, 0, 'Norethisterone', 'Glucose Intolerance', 'Impaired glucose tolerance has been observed in some patients administered oral contraceptives and appears to be related primarily to the estrogen dose.  However, progestogens can increase insulin secretion and produce insulin resistance to varying degrees, depending on the agent.  Patients with diabetes mellitus should be monitored more closely during therapy with estrogens and/or progestogens, and adjustments made accordingly in their antidiabetic regimen.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1474, 0, 'Norethisterone', 'Eye Diseases', 'Estrogens and progestogens may cause retinal thrombosis.  Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions.  Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted.  Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1475, 0, 'Norethisterone', 'Thyroid Diseases', 'When administering estrogen and/or progestogen therapy in patients with thyroid disorders, clinicians should be aware that these hormones may affect thyroid function tests.  Changes have mostly been reported with the use of combination oral contraceptives.  Specifically, thyroid-binding globulin (TBG) may be increased, resulting in elevated circulating total thyroid hormone, as measured by PBI (protein-bound iodine), T4 by column or radioimmunoassay, or T3 by radioimmunoassay.  Free T3 resin uptake may be decreased.  On the contrary, a decrease in TBG and, consequently, thyroxine concentration, has been reported by the manufacturers of the progestin-only (norethindrone) oral contraceptives.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1476, 0, 'Norethisterone', 'Hyperlipidemias', 'Some progestogenic agents may elevate plasma LDL levels and/or lower HDL levels, although data have been inconsistent.  Patients with preexisting hyperlipidemia may require closer monitoring during progestogen therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1477, 0, 'Norethisterone', 'Weight Gain', 'Progestogens can cause weight gain, which may be significant (as is the case with parenteral medroxyprogesterone) and undesirable in obese patients attempting to lose weight.', '1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1478, 0, 'Norepinephrine', 'Venous Thromboembolism', 'Norepinephrine injection should not be given to patients with mesenteric or peripheral vascular thrombosis (because of the risk of increasing ischemia and extending the area of infarction) unless, in the opinion of the attending physician,the administration of norepinephrine is necessary as a life- saving procedure.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1479, 0, 'Norepinephrine', 'Dehydration', 'The use of sympathomimetic amines has been infrequently associated with significant hypotension especially in dehydrated patients secondary to the drug''s beta-2 mediated vasodilation.  Hypovolemia should be corrected, if possible, before administering sympathomimetic amines.  Blood pressure and ECG should be monitored at regular intervals.  Monitoring of cardiac output and pulmonary wedge pressure may also be desired.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1480, 0, 'Norepinephrine', 'Acidosis', 'Acidosis, hypoxia, and hypercapnia may reduce the effectiveness of sympathomimetic amines in raising blood pressure.  These conditions should be corrected before initiating therapy with sympathomimetic amines, if possible.  Monitoring the patients acid-base balance, carbon dioxide levels, and oxygen saturation is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1481, 0, 'Nortriptyline', 'Anticholinergic Syndrome', 'Tricyclic and tetracyclic antidepressants (TCAs) have anticholinergic activity, to which elderly patients are particularly sensitive.  Tertiary amines such as amitriptyline and trimipramine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with TCAs should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  In patients with angle-closure glaucoma, even average doses can precipitate an attack.  Glaucoma should be treated and under control prior to initiation of therapy with TCAs, and intraocular pressure monitored during therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1482, 0, 'Nortriptyline', 'Cardiovascular Diseases', 'Tricyclic and tetracyclic antidepressants (TCAs) may cause orthostatic hypotension, reflex tachycardia, syncope, and dizziness, particularly during initiation of therapy or rapid escalation of dosage.  Imipramine appears to have the greatest propensity to induce these effects, while secondary amines such as nortriptyline may do so less frequently.  Tolerance to the hypotensive effects often develops after a few doses to a few weeks.  Rarely, collapse and sudden death have occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include tachycardia, arrhythmias, heart block, hypertension, thrombosis, thrombophlebitis, myocardial infarction, strokes, congestive heart failure, and ECG abnormalities such as PR and QT interval prolongation.  Therapy with TCAs should be avoided during the acute recovery phase following myocardial infarction, and should be administered only with extreme caution in patients with hyperthyroidism, a history of cardiovascular or cerebrovascular disease, or a predisposition to hypotension.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  Many of the newer antidepressants, including bupropion and the selective serotonin reuptake inhibitors (SSRIs), are considerably less or minimally cardiotoxic and may be appropriate alternatives.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1483, 0, 'Nortriptyline', 'Pheochromocytoma', 'Tricyclic and tetracyclic antidepressants (TCAs) may potentiate the effects of circulating catecholamines.  Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas.  Therapy with TCAs should be administered cautiously in patients with these tumors.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1484, 0, 'Nortriptyline', 'Acute Myocardial Infarction Recovery', 'The use of most tricyclic antidepressants is contraindicated in patients that are going through the acute recovery period after a myocardial infarction.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1485, 0, 'Nortriptyline', 'Depressive Disorder', 'Adult and pediatric patients with depression may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1486, 0, 'Nortriptyline', 'Epilepsy', 'Tricyclic antidepressants (TCAs), can lower the seizure threshold and trigger seizures.  These drugs should be used with extreme caution in patients with a history of seizures, or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.  Daily dose restrictions might apply for specific antidepressants.  Physicians are encouraged to get additional dosing recommendations on the manufacturer''s prescribing information.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1487, 0, 'Nortriptyline', 'Bone Marrow Failure Disorders', 'The use of tricyclic and tetracyclic antidepressants (TCAs) has rarely been associated with bone marrow suppression.  Leukopenia, agranulocytosis, thrombocytopenia, anemia, eosinophilia, purpura, and pancytopenia have been reported with some TCAs.  Patients with preexisting bone marrow suppression or blood dyscrasias receiving TCAs should be monitored closely during therapy for further decreases in blood counts.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1488, 0, 'Nortriptyline', 'Diabetes Mellitus', 'Both elevation and lowering of blood sugar levels have been reported with the use of some tricyclic antidepressants (TCAs).  Rarely, these effects have also occurred with maprotiline, a tetracyclic antidepressant.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents, particularly during dosage escalation or whenever dosage has been altered.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1489, 0, 'Nortriptyline', 'Liver Diseases', 'Tricyclic and tetracyclic antidepressants (TCAs) are known to undergo metabolism in the liver.  Some of the metabolites, such as those of imipramine, clomipramine and desipramine, may be pharmacologically active.  Many of the metabolites are also excreted by the kidney.  There are very limited data concerning the use of TCAs in patients with renal and/or liver disease.  Therapy with TCAs should be administered cautiously in patients with significantly impaired renal or hepatic function.  Dosage adjustments may be necessary.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1490, 0, 'Nortriptyline', 'Schizophrenia', 'Tricyclic antidepressants (TCAs) may aggravate symptoms of psychosis in schizophrenic patients, particularly those with paranoid symptomatology.  Depressed patients, usually those with bipolar disorder, may experience a switch from depression to mania or hypomania.  These occurrences have also been reported rarely with the tetracyclic antidepressant, maprotiline.  Therapy with these agents should be administered cautiously in patients with schizophrenia, bipolar disorder, or a history of mania.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1491, 0, 'Nortriptyline', 'Tardive Dyskinesia', 'Tricyclic and tetracyclic antidepressants (TCAs) have anticholinergic activity, to which elderly patients are particularly sensitive.  Tertiary amines such as amitriptyline and trimipramine tend to exhibit greater anticholinergic effects than other agents in the class.  As with other drugs that possess anticholinergic activity, TCAs may aggravate tardive dyskinesia or induce previously suppressed symptoms.  Patients with tardive dyskinesia requiring therapy with TCAs should be monitored for exacerbation of the condition.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1492, 0, 'Nortriptyline', 'Alcoholic Intoxication', 'Tricyclic antidepressants can enhance the response to alcohol.  In patients who may use alcohol excessively, it should be borne in mind that the potentiation may increase the danger inherent in any suicide attempt or overdosage.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1493, 0, 'Nortriptyline', 'Bipolar Disorder', 'A major depressive episode can be the initial presentation of bipolar disorder.  Patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder prior to initiating treatment with a tricyclic antidepressant.  This screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.  It should be noted that tricyclic antidepressants are not approved for use in treating bipolar depression.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1494, 0, 'Nortriptyline', 'Glaucoma', 'Tricyclic antidepressants as other type of antidepressants have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with anatomically narrow angle or history of glaucoma.  Doxepin hydrochloride capsules are contraindicated in patients with glaucoma.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1495, 0, 'Nortriptyline', 'Neutropenia', 'The use of some tricyclic antidepressants has been associated with neutropenia (ANC < 500/mm3) and agranulocytosis (ANC < 500/mm3).  Leukocyte and differential blood counts should be performed in patients that develop fever and sore throat during treatment.  Therapy should be discontinued if there is evidence of pathologic neutrophil depression.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1496, 0, 'Nortriptyline', 'Thyroid Diseases', 'Most tricyclic antidepressants should be administered with caution in hyperthyroid patients or those receiving thyroid medication as they may develop arrhythmias when these drugs are given.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1497, 0, 'Nortriptyline', 'Urinary Retention', 'Due to their anticholinergic properties, tricyclic antidepressants should be administered with caution in patients with history of urinary retention.  Particularly doxepin hydrochloride capsules are contraindicated in patients with tendency to urinary retention.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1498, 0, 'Obeticholic acid', 'Cholestasis', 'Obeticholic acid is contraindicated in patients with complete biliary obstruction.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1499, 0, 'Obeticholic acid', 'Liver Failure', 'In postmarketing reports, hepatic decompensation and failure, in some cases fatal, have been reported in patients with primary biliary cholangitis (PBC) with decompensated cirrhosis or Child-Pugh Class B or C hepatic impairment when obeticholic acid was dosed more frequently than recommended.  The recommended starting dosage is 5 mg once weekly for patients with Child-Pugh Class B or C hepatic impairment or a prior hepatic decompensation event.  Patients in treatment should be closely monitored for progression of PBC disease, including liver- related complications, with laboratory and clinical assessments.  Dosage adjustment, interruption or discontinuation may be required.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (1500, 0, 'Obeticholic acid', 'Hyperlipidemias', 'Patients with primary biliary cholangitis generally exhibit hyperlipidemia characterized by a significant elevation in total cholesterol primarily due to increased levels of high-density lipoprotein-cholesterol (HDL-C).  Exercise care when using obeticholic acid in patients with lipids disorder.  It is recommended to monitor patients for changes in serum lipid levels during treatment with obeticholic acid.  For patients who do not respond to treatment after 1 year at the highest recommended dosage that can be tolerated (maximum of 10 mg once daily), and who experience a reduction in HDL-C, weigh the potential risks against the benefits of continuing treatment.', '2', 'DDInter', 0);
